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Summary 
Tuberculosis has been declared a global public health emergency by the World 
Health Organization since 1993. Despite international control programmes, 
the worldwide burden of disease remains enormous, and the problem is 
compounded by the emergence of drug-resistant strains and synergistic co-
infection with HIV. Efforts to discover novel drugs have largely been focused 
on targeting the bacterium directly. Alternatively, manipulating the host 
immune response may represent a valuable approach to enhance 
immunological clearance of the bacilli, necessitating a deeper understanding 
of the immune mechanisms associated with protection against M. tuberculosis 
infection. In this Thesis, we report and discuss our experimental findings on 
two aspects of host immunity to M. tuberculosis infection: the role of Annexin 
A1 (ANXA1), a protein expressed endogenously by a variety of immune cells, 
and the role of CLEC9A+ dendritic cells (DCs), which includes CD103+ 
migratory DCs in the lung and CD8+ DCs in the lymphoid organs.  
 
First, using an ANXA1−/− mouse model of pulmonary M. tuberculosis 
infection, we describe how ANXA1 influences the immune response to M. 
tuberculosis infection. A link between ANXA1 and TB was first established 
only recently; virulent M. tuberculosis was shown in vitro to inhibit the 
ANXA1-dependent apoptotic pathway in order to promote dissemination via 
host necrosis. However, the in vivo effect of ANXA1 was not investigated. We 
showed that ANXA1 plays an important role in controlling bacterial load and 
restraining immunopathology. While ANXA1 has little effect on M. 
tuberculosis infection profile in macrophages, it appears to be critically 
  xi 
involved in regulating the adaptive immune response via its impact on DC 
functions, specifically cytokine production, maturation and ability to activate 
naïve T cells.  
 
Second, using GFP-expressing bacteria, we show that DCs increase in 
importance as a mycobacterial reservoir relative to their primary hosts, 
alveolar macrophages, as M. tuberculosis infection progresses. Using 
CLEC9A-DTR transgenic mice enabling the inducible depletion of CLEC9A+ 
DCs, we established that CD103+ DCs contribute to the control of bacterial 
burden and play an important role in the initiation of T cell responses during 
M. tuberculosis infection. Our findings thus support a crucial role for the lung 
CD103+ DC subset in the rapid mobilisation of bacteria from the lung to the 
draining LN soon after pulmonary exposure to M. tuberculosis, which is a 
critical determinant of host resistance.  
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1.1.  Epidemiology of TB 
Tuberculosis (TB) is the second leading cause of death due to a single 
infectious agent worldwide, after the human immunodeficiency virus (HIV). 
The World Health Organization (WHO) declared TB a global public health 
emergency in 1993, and has since implemented a multitude of strategies to 
tackle the problem, such as the “Stop TB Strategy”, which underpins a 
concerted effort amongst various international partners in “The Global Plan to 
Stop TB: 2006-2015”. While the mortality rate has decreased 45% between 
1990 and 2013, the global burden of TB remains enormous. In 2013, there 
were an estimated 9 million new TB cases—of which 1.1 million were HIV-
positive—and 1.5 million TB-related deaths (Figure 1.1) (WHO, 2014). 
 
TB can affect people of all ages and occurs in every part of the world, 
disproportionately affecting the poorest in both developed and developing 
countries. Ninety-five percent of cases and deaths occur in developing 
countries. The absolute number of cases is highest in Asia, with China and 
India having the greatest disease burden. Propelled by the HIV epidemic, Sub-
Saharan Africa has the highest rates of active tuberculosis per capita (WHO, 
2014). In the United States and most Western European countries, most cases 
occur in foreign-born residents and recent immigrants from TB-endemic 
countries (CDC, 2014; ECDPC, 2013).  
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Figure 1.1. Estimated TB incidence rates in 2013. Adapted from “Global 
Tuberculosis Report 2014” by WHO, 2014, Global Tuberculosis Report 2014. 
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1.2.  Aetiology and transmission of TB 
1.2.1.  M. tuberculosis is the main cause of TB in humans 
The principal aetiological agent of the human disease is the acid-fast, aerobic, 
non-spore forming, non-motile bacillus Mycobacterium tuberculosis, which 
was first characterised by Robert Koch in 1882 (Koch 1982). M. tuberculosis 
can be cultured in the laboratory, typically using Lowenstein-Jensen media or 
Middlebrook media supplemented with oleic acid, albumin, dextrose and 
catalase (OADC), although it has an exceptionally slow doubling time of 16 to 
20 hours compared to other laboratory-cultured bacteria (Pfyffer, 2007). It has 
an unusual cell wall that is rich in lipids such as mycolic acids, a key virulence 
factor (Barry 2001), which also improves its survival outside a host by 
rendering it resistant to weak disinfectants and desiccation (Kramer, 
Schwebke, & Kampf, 2006). The mycobacterial cell wall does not retain the 
crystal violet stain used in the Gram staining procedure; instead, the Ziehl-
Neelson stain is applied in order to confirm the presence of these acid-fast 
bacilli (Pfyffer, 2007). 
 
In addition to M. tuberculosis, several other mycobacteria species, including 
M. africanum, M. bovis, M. canetti, M. microti, M. caprae and M. pinnipedii, 
comprise what is known as the “M. tuberculosis complex” (MTBC) (Warren 
et al., 2006). All members of the MTBC are capable of causing tuberculosis in 
humans. M. africanum is not widespread, but it is an important cause of TB in 
parts of Africa (de Jong, Antonio, & Gagneux, 2010). M. bovis transmission 
from cattle to humans via the consumption of infected milk was historically a 
major cause of TB, but with the introduction of pasteurisation, now accounts 
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for only a small number of cases (Thoen, Lobue, & de Kantor, 2006). An 
attenuated form of M. bovis, known as bacille de Calmette et Guérin (BCG) is 
used as a vaccine. TB cases attributed to M. canetti, M. microti, M. caprae and 
M. pinnipedii are regarded as rare zoonoses (Panteix et al., 2010; Rodríguez et 
al., 2009; Kiers, Klarenbeek, Mendelts, Van Soolingen, & Koëter, 2008), 
although M. canetti-related TB has recently been proposed to be an emerging 
disease in the Horn of Africa (Fabre et al., 2010). Other known pathogenic 
mycobacteria include M. leprae, which causes leprosy, and M. avium and M. 
kansasii, which are associated with non-tuberculous mycobacterial lung 
disease (Griffith 2010). 
 
1.2.2.  Airborne transmission of TB  
TB is transmitted via inhalation of aerosolised droplets (0.5 to 5µm in 
diameter) containing infectious bacilli that are expelled from a person with 
active pulmonary disease through respiratory manoeuvres such as coughing or 
sneezing. The infectious dose of M. tuberculosis is extremely low; in humans, 
the ID50 is estimated to be one to 10 bacilli (Pfyffer, 2007). Low aerosol 
doses of M. tuberculosis have also been shown to be able to cause infection in 
various animal models of tuberculosis, and low-dose small animal models are 
commonly used in drug and vaccine testing (Gupta & Katoch, 2005). In 
particular, low-dose mouse models typically involve inoculation with 50 to 
500 colony-forming units (CFU), and an ultra-low dose mouse model using 
one to 11 CFU has been proposed (Saini et al., 2012). Being a highly 
communicable, almost exclusively airborne infection has obvious implications 
on the epidemiology and approaches to infection control of TB.   
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1.3.  Pathogenesis of TB: the spectrum of active and latent TB 
1.3.1.  Pathogenesis depends on environmental, host and microbial factors 
Development of TB is dependent on a complex interplay between the 
environment, the host and the pathogen. Environmental and socio-
demographic risk factors include residence in an endemic area, poverty, 
overcrowding, or employment as a healthcare worker in contact with TB 
patients. Host factors strongly influence disease progression after infection. 
Individuals with immune systems compromised by disease, most notably HIV 
infection, or due to immunosuppressive medications, such as corticosteroids, 
tumor necrosis factor (TNF) inhibitors or cytotoxic chemotherapeutic agents, 
are more susceptible, as are those with chronic diseases such as diabetes. 
Young age (less than 4 years), malnutrition, and substance abuse are other 
independent risk factors for disease. The increase in risk is especially dramatic 
(26 to 31 times higher) for HIV-positive individuals (WHO, 2014). Recent 
studies suggest that particular combinations of host and Mycobacterium 
tuberculosis genotypes are associated with disease severity and increased risk 
of active TB (Nahid et al., 2010; Gagneux et al., 2006). 
 
Upon initial infection, some individuals progress rapidly to active TB, known 
as primary TB. This occurs more commonly in children (known as milliary 
TB) but is also possible in adults (Frieden, Sterling, Munsiff, Watt, & Dye, 
2003). The majority (about 90%) of immunocompetent individuals will 
contain the infection and remain asymptomatic, or latently infected, for many 
years after exposure. Approximately one-third of the world’s population is 
estimated to be infected with M. tuberculosis (WHO, 2014). Based on 
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epidemiological and modelling studies, latent individuals have a 10% risk of 
developing active disease in their lifetime, which is referred to as post-primary 
TB or reactivation TB (Figure 1.2). In comparison, this value represents the 
annual risk for HIV co-infected individuals (Andrews et al., 2012; Dye, 
Scheele, Dolin, Pathania, & Raviglione, 1999).  A study suggests that some 
individuals are able to eliminate acute M. tuberculosis infection altogether 
(Ewer et al., 2006). 
 
 
Figure 1.2. The spectrum of active and latent TB in humans. M. 
tuberculosis bacteria is transmitted via airborne droplets expelled by a person 
with active pulmonary TB. Upon inhalation of infectious droplet nuclei, most 
people remain asymptomatic, defined as having latent TB. Normal individuals 
who are latently infected have a 10% lifetime risk of developing active TB. 
Adapted from “The immune response in tuberculosis” by A. O’Garra et al., 
2013, Annual Review in Immunology	   31, pp. 475-527. Copyright 2014 by 
Annual Reviews Inc. Adapted with permission.  
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1.3.2.  Active TB is complex and difficult to diagnose  
Active TB is complex and heterogeneous. Primary and reactivation TB may 
differ in terms of both clinical presentation and temporal pathogenesis. TB is 
primarily a pulmonary disease but M. tuberculosis is able to disseminate to a 
variety of other organs, including the lymph nodes (LN), spleen, liver, bone 
and meninges, thereby causing extrapulmonary forms of the disease. 
Extrapulmonary TB occurs in 10 to 42% of patients, depending on age, 
genetics, immune status, underlying medical conditions, and also the genotype 
of the infecting strain of M. tuberculosis (Caws et al., 2008). Symptoms of 
active TB typically include systemic features such as fever, night sweats, loss 
of appetite and weight, as well as localised manifestations of tissue destruction 
at the site of active infection where actively replicating, transmissible bacteria 
reside—in the case of pulmonary TB, chronic coughing, sputum production, 
and hemoptysis (Brändli 1998).  
 
Diagnosis of active TB, especially extrapulmonary TB, is challenging because 
clinical presentation is varied and overlaps with many other conditions such as 
pneumonia, cancer and sarcoidosis (Storla, Yimer, & Bjune, 2008). Sputum 
microscopy and culture of patient samples, followed by drug-susceptibility 
tests, which altogether takes several weeks, are currently the standard methods 
for diagnosing active TB (Steingart et al., 2006). A new automated, PCR-
based molecular diagnostic assay called Xpert MTB/RIF has recently gained 
WHO approval, and is far more rapid and sensitive, detecting M. tuberculosis 
and rifampicin resistance within hours (Boehme et al., 2010). 
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1.3.3.  Latent TB: a heterogeneous state with diverse clinical outcomes 
The asymptomatic latent state is maintained by a normal, healthy host immune 
response that keeps the replication of the pathogen under control, although it 
does not completely eradicate it (Gomez & McKinney, 2004). It has been 
suggested that the M. tuberculosis strain responsible for the initial infection 
has the ability to cause reactivation TB up to an interval of 30 years from the 
original exposure (Lillebaek et al., 2003).  
 
Clinical diagnosis of latent TB infection (LTBI) is based on either a classic 
tuberculin skin test (TST) or an interferon (IFN)-gamma (IFNγ) release assay 
(IGRA). In the TST, a purified protein derivative (PPD) commercially 
prepared from the culture filtrate of M. tuberculosis is intra-dermally injected 
and the delayed-type hypersensitivity response is measured. However, as the 
antigenic composition of PPD is not unique to M. tuberculosis and overlaps 
with BCG as well as non-tuberculous environmental mycobacteria, the TST 
has limited specificity. False positive TST results are likely in those who have 
been vaccinated or exposed to environmental mycobacteria; yet, it is still the 
widely preferred and often only available method especially in low-income 
areas because it is relatively inexpensive. IGRAs assess host reactivity to more 
specific M. tuberculosis antigens, such as early secretory antigen target-6 
(ESAT-6) and culture filtrate protein-10 (CFP-10), by measuring IFNγ 
production by blood cells using an enzyme-linked immunosorbent assay 
(ELISA) after whole blood incubation, or alternatively, using an enzyme-
linked immunospot (ELISpot) technique after incubation with isolated 
peripheral blood mononuclear cells (PBMCs). While the development of 
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IGRAs is progressive, no test is currently available to distinguish between 
latent and active TB (McNerney et al., 2012). 
 
Moreover, it is becoming increasingly recognized that what is simply 
diagnosed as LTBI in reality represents heterogeneous host immune responses 
to infection and consequently, diverse clinical outcomes (Lin et al., 2014). As 
mentioned, M. tuberculosis infection is diagnosed based on the host's 
reactivity to mycobacterial antigens using either the traditional TST or the 
more recent IGRAs, However, positive TST and/or IGRA results are 
indistinguishable between individuals who have successfully cleared infection 
by developing a detectable adaptive immune response, individuals who have 
mounted a detectable adaptive immune response but remain infected yet 
asymptomatic, and individuals with established or subclinical active disease. 
Likewise, negative test results reflect several possibilities: that the individual 
was exposed to M. tuberculosis but it was insufficient to cause infection, that 
the individual had cleared infection without developing a detectable adaptive 
immune response, or that the immune response of an infected individual is 
simply too localised or too weak to be detected systemically (O'Garra et al., 
2013; Barry et al., 2009) (Figure 1.3).  
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Figure 1.3. The heterogeneous consequences of M. tuberculosis infection. 
The implications of the heterogeneity of the host immune response to M. 
tuberculosis infection are becoming increasingly recognised. The active and 
latent states simplistically represent two clinically diagnosable extremes, but 
the latent state itself broadly encompasses a multitude of conditions with 
potentially different pathophysiological outcomes. Adapted from “The 
immune response in tuberculosis” by A. O’Garra et al., 2013, Annual Review 
in Immunology	   31, pp. 475-527. Copyright 2014 by Annual Reviews Inc. 
Adapted with permission. 
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1.4.  Prevention and treatment of TB 
1.4.1.  Protection by BCG immunisation and vaccines under development 
The BCG vaccine was introduced in 1928, almost 90 years ago. It continues to 
be the only widely available vaccine and is given to infants. While there is 
some consensus about the protective effect of BCG vaccine against 
disseminated forms of childhood TB (Colditz et al., 1995), meta-analysis of 
controlled clinical trials reflect a variable, generally poor efficacy of the BCG 
vaccine in the prevention of infectious pulmonary TB in adults (Colditz et al., 
1994).  
 
Currently, more than 30 vaccines are under development, 12 of which have 
entered clinical trials (WHO, 2014). Of all the vaccine candidates, MVA85A, 
an attenuated version of the modified Vaccinia Ankara virus (originally 
developed as a smallpox vaccine) expressing the immunodominant antigen 
Ag85A, has by far been the most extensively tested in multiple animal models 
with consistently encouraging results (White et al., 2013; Williams et al., 
2005; Goonetilleke et al., 2003). In humans, a phase I clinical trial reported no 
serious adverse reactions and strong Ag85-specific CD4+ T cell responses in 
healthy adult volunteers (Meyer et al., 2013). Unfortunately, in a recently-
completed phase IIb clinical trial to test its efficacy and safety as a boost 
strategy in BCG-immunised, HIV-negative infants, MVA85A was well 
tolerated but efficacy against TB was a dismal 17.3% (Tameris et al., 2013). 
Notably, immunisation with M. vaccae, a whole-cell mycobacterial vaccine, 
was demonstrated in a phase III clinical trial to be a viable strategy (39% 
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efficacy) for the prevention of HIV-associated tuberculosis in BCG-
immunised, HIV-positive adults (von Reyn et al., 2010). 
1.4.2.  Treatment of TB 
Presently, the standard treatment for drug-sensitive active TB is a 6-month 
regimen comprising four first-line drugs (isoniazid, rifampin, pyrazinamide 
and ethambutol). The initial “intensive” phase of the regimen aims to 
eliminate actively replicating bacilli, and the following “continuation” phase 
targets persisting bacilli (Sia & Wieland, 2011). This potentially achieves cure 
rates of more than 90% under strict oversight (Combs, O'Brien, & Geiter, 
1990). Latent individuals with increased risk for active TB require preventive 
treatment, most commonly with isoniazid alone for 9 months or longer in HIV 
co-infected patients in areas with high prevalence rates of TB (Martinson et 
al., 2011). Challenges in therapy include inconsistent quality of drugs, toxicity 
and/or other side effects, and poor compliance due to the long treatment 
period. The clinical management of active TB for HIV co-infected patients on 
antiretroviral therapy is further complicated due to pharmacokinetic 
interactions (Khan et al., 2010). 
 
1.4.3.  Drug-resistant TB 
In the case of drug resistance or intolerance to first-line drugs, second-line 
drugs may be used. Second-line agents include fluoroquinolones and 
injectable agents, and are so classified due to relative scarcity of clinical data, 
unfavourable or poorly characterised pharmacokinetic profile, and/or 
increased incidence and severity of adverse reactions. In 2013, 5% of TB 
cases worldwide (3.5% of new cases and 20.5% of previously treated cases) 
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were estimated to be multi-drug resistant (MDR). Extensively drug-resistant 
(XDR) TB was reported by 100 countries (WHO, 2014). MDR-TB is defined 
as resistance to the two main first-line antibiotics, isoniazid and rifampicin. 
XDR-TB is defined as resistance to isoniazid and rifampicin, and additionally, 
to any fluoroquinolone and any of the three second-line injectables: amikacin, 
capreomycin, and kanamycin (Blumberg et al., 2003). Drug-resistant TB is 
hard to diagnose and treat in TB-endemic countries, with death rates as high as 
98% amongst HIV co-infected people (Dheda et al., 2010). The treatment of 
drug-resistant TB requires expert opinion and customized drug regimens 
comprising of both first-line and second-line drugs, and is associated with a 
high probability of intolerance and severe toxicity (Falzon et al., 2011).  
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1.5.  Initiation of infection and the innate immune response  
1.5.1.  Macrophages are the first to be infected by M. tuberculosis and fail 
to restrict an initial phase of exponential bacterial growth  
Aerosolized droplets containing infectious bacilli are inhaled into the lung 
airways and reach the pulmonary alveoli, where they are taken up by alveolar 
macrophages (Figure 1.4A). Entry of M. tuberculosis into macrophages is 
mediated by a variety of cell-surface receptors, including mannose receptors, 
complement receptors and scavenger receptors (Kleinnijenhuis, Oosting, 
Joosten, Netea, & Van Crevel, 2011). Internalised bacteria are contained 
within phagosomes where mycobacteria replicate freely. Extensively, studies 
have shown that in contrast to non-viable and non-virulent mycobacteria, 
virulent strains arrest phagosome maturation and phagolysosomal fusion 
(Philips 2008), block accumulation of reactive oxygen and nitrogen species 
(Miller et al., 2004; Darwin, Ehrt, Gutierrez-Ramos, Weich, & Nathan, 2003), 
neutralise the acidification of mycobacterial phagosomes (Wong, Bach, Sun, 
Hmama, & Av-Gay, 2011; Sturgill-Koszycki et al., 1994), and interfere with 
host signalling pathways (Koul, Herget, Klebl, & Ullrich, 2004) in ways that 
promote their persistence and active replication inside the mycobacterial 
compartment. Critically, the bacilli-containing phagosome is accessible within 
minutes to exogenously administered molecules such as recycled transferrin 
and is enriched in transferrin receptor/CD71 (Nguyen & Pieters, 2005), 
allowing intracellular mycobacteria to access extracellular components and 
possibly essential nutrients, such as iron, via the host cell’s recycling pathway. 
This underscores the macrophage’s role as a central reservoir of mycobacterial 
replication (Rohde, Yates, Purdy, & Russell, 2007). However, upon activation 
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of the host macrophage with IFNγ (Herbst, Schaible, & Schneider, 2011), 
adenosine triphosphate (ATP) (Kusner & Barton, 2001), or certain lipids 
(Anes et al., 2003), the mycobacterial vacuole accumulates proton ATPases, 
acidifies and eventually matures into a phagolysosome, killing the bacteria 
inside. However, this killing is a protracted, inefficient process; viable 
mycobacteria can still be detected in IFNγ-activated macrophages days after 
in vitro infection (Schnappinger et al., 2003). M. tuberculosis mutants unable 
to arrest phagolysosomal fusion have been found to have impaired growth but 
were still able to persist inside host phagolysosomes (Pethe et al., 2004). 
Increasingly, M. tuberculosis has been demonstrated to possess strategies and 
mechanisms that allow this pathogen to persist within the hostile 
microenvironment of the lysosomal compartment within activated 
macrophages (Ehrt & Schnappinger, 2009). 
 
Macrophage death by apoptosis functions as an anti-mycobacterial mechanism 
associated with reduced pathogen viability and enhanced immunity (Behar et 
al., 2011; Kelly, ten Bokum, O'Leary, O'Sullivan, & Keane, 2008; Keane, 
Remold, & Kornfeld, 2000), as the cell membrane remains intact and contains 
the spread of bacteria. However, virulent strains of M. tuberculosis can inhibit 
apoptotic envelope formation, driving macrophage necrosis and the release of 
viable bacilli (Gan et al., 2008). Additionally, while it was previously thought 
that M. tuberculosis resides strictly within its membrane-bound phagosome 
(Clemens, Lee, & Horwitz, 2002), cryo-immunogold electron microscopy has 
revealed that mycobacteria are able to translocate into the cytosol in myeloid 
cells, specifically macrophages and dendritic cells (van der Wel et al., 2007). 
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Phagosomal rupture appears to be a pathogenic feature of virulent 
mycobacteria and results in host cell necrosis (Simeone et al., 2012).  
 
Necrotic death of infected resident alveolar macrophages results in a localised 
pro-inflammatory response that attracts mononuclear cells from the blood to 
the lungs (Figure 1.4B). Monocytes accumulate and differentiate into tissue 
macrophages that also readily phagocytose but do not kill the mycobacteria, 
resulting in a period of exponential mycobacterial growth within host 
macrophages until the emergence of an adaptive immune response (Russell, 
Cardona, Kim, Allain, & Altare, 2009). Infected macrophages may further 
facilitate the dissemination of bacteria by migration to distal sites in the lungs 
(Davis et al., 2002). In the lung parenchyma, bacteria are also phagocytosed 
by neutrophils (Eum et al., 2010; Eruslanov et al., 2005) and dendritic cells 
(Tailleux et al., 2003a). 
 
1.5.2.  Neutrophil accumulation in the lungs is associated with pathology  
Neutrophils are the main infected phagocytes in the airways of patients with 
active pulmonary TB (Eum et al., 2010). In mice, it has been shown that 
neutrophils can capture mycobacteria in peripheral tissues and transport them 
to the LN (Abadie et al., 2005). Furthermore, it is suggested that neutrophils 
deliver M. tuberculosis bacilli to dendritic cells in a form that enhances their 
function as initiators of CD4+ T cell activation (Blomgran & Ernst, 2011). As 
with macrophages, virulent M. tuberculosis also inhibits apoptosis of 
neutrophils, resulting in delayed activation of naïve CD4+ T cells in the lung-
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draining LN and impaired induction of T cell responses (Blomgran, 
Desvignes, Briken, & Ernst, 2012).  
 
However, while it has been reported that neutrophils regulate early granuloma 
formation after aerosol M. tuberculosis infection via CXCR3-signaling 
chemokines (Seiler et al., 2003), multiple studies suggest that the presence of 
neutrophils in TB contributes to pathology rather than protection of the host. 
Susceptible mouse strains show enhanced recruitment of neutrophils into the 
lungs (Keller et al., 2006; Eruslanov et al., 2005), and in patients with active 
TB, respiratory failure and mortality are associated with increased blood 
neutrophil levels (Lowe et al., 2013). Neutrophils are dominant producers of 
the anti-inflammatory cytokine IL-10 in the lung, and depletion of neutrophils 
reduces bacterial load (Zhang, Majlessi, Deriaud, Leclerc, & Lo-Man, 2009). 
Recently, it was shown that IFNγ inhibits neutrophil survival as well as 
accumulation in the infected lungs, thus lowering inflammation and improving 
the disease outcome (Nandi & Behar, 2011), suggesting that neutrophilia 
connotes failure of the T helper (Th) 1 immune response. 
 
1.5.3.  DCs deliver antigen from the lungs to the LN and initiate T cell 
responses  
It is suggested that dendritic cell (DC) uptake of M. tuberculosis is mediated 
by binding to DC-specific intercellular adhesion molecule-3 grabbing non-
integrin (DC-SIGN) (Tailleux et al., 2003b). Mycobacteria-containing 
phagosomes in DCs display arrested acidification and phagolysosomal fusion 
as in macrophages. DCs are also permissive to M. tuberculosis infection, but 
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unlike macrophages, not intracellular replication. Reduced transport between 
the mycobacterial compartment and host cell recycling and biosynthetic 
pathways, resulting in restricted mycobacterial access to nutrient sources is 
believed to explain the diminished replicative capacity of M. tuberculosis 
within DCs compared to macrophages (2003a).  
 
DCs are rare cells specialised for the capture, processing and presentation of 
antigens to T cells (Steinman 2012), thus their role in the initiation of T cell 
responses to M. tuberculosis is expected. However, how DCs initiate this 
response is complicated by the context of their interactions with infected 
macrophages and neutrophils. Contact with apoptotic cells containing M. 
tuberculosis bacilli accelerates their functions in bacterial acquisition, 
trafficking to LN, and T cell priming (Blomgran et al., 2012). Analysis of 
mouse lungs and LN show that along with macrophages and neutrophils, DCs 
are also infected early on after aerosol infection with M. tuberculosis, with the 
bacterial load in the lung-draining LN reaching a peak three weeks after 
infection (Wolf et al., 2007). The transient depletion of DCs was shown to 
significantly delay priming of antigen-specific CD4+ T cells, resulting in 
uncontrolled M. tuberculosis replication in the lungs and spleen from infected 
mice (Tian, Woodworth, Sköld, & Behar, 2005). Findings from a separate 
study by Humphreys and colleagues using BCG are consistent with a model in 
which mycobacterial extrapulmonary dissemination is initiated by the 
migration of infected DCs to the draining LN (Humphreys et al., 2006). Taken 
together, these studies suggest that the migratory properties of infected DCs is 
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crucial to the delivery of antigen from the site of infection to the draining LN, 
where the initial activation of T cells occurs (Wolf et al., 2008).  
 
In addition, DCs are unique in their ability to activate unconventional subsets 
of T cells via human leucocyte antigen (HLA)-E (Heinzel et al., 2002) and 
CD1 (Brigl & Brenner, 2004) that are not present on macrophages. M. 
tuberculosis may exert its virulence by interfering with DC function, as DCs 
infected in vivo stimulate naïve T cells less efficiently than uninfected DCs 
(Wolf et al., 2007). 
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1.6.  Granuloma formation  
1.6.1.  Granulomas are the characteristic pathological feature of TB 
Granulomas are the hallmark pathological lesions in chronic infection with 
tuberculous mycobacteria. The granuloma was first described in 1679 in 
tuberculous lungs and called a tubercle (Sylvius, 1679); accumulation of 
evidence associating the presence of tubercles with the disease prompted the 
naming of “tuberculosis” in 1839 (Sakula, 1982).  
 
1.6.2.  Macrophages initiate granuloma formation by secreting critical 
soluble factors 
Interaction with M. tuberculosis induces macrophages to secrete a variety of 
pro-inflammatory cytokines (Cooper, Mayer-Barber, & Sher, 2011) and 
chemokines (Algood, Chan, & Flynn, 2003), which attract successive waves 
of immune cells to the lung (Figure 1.4C). Chemokines are required for 
cellular recruitment and retention; in particular, chemokines binding to the 
CCR2 receptor (CCL2/MCP-1, CCL12 and CCL13) play a critical role in the 
early recruitment of macrophages (2003). In vivo studies of infected macaque 
monkeys show that CXCR3-binding cytokines CXCL9, CXCL10 and 
CXCL11 are extensively up-regulated (Fuller, Flynn, & Reinhart, 2003). 
Central to granuloma formation is the production of TNF, initially by infected 
macrophages, and subsequently also by recruited T cells. Sustained TNF 
signalling maintains local chemokine concentrations required for re-modeling 
the infection site (Chakravarty et al., 2008; Algood, Lin, & Flynn, 2005; 
Roach et al., 2002).  
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1.6.3.  Containment of infection through cellular recruitment and 
remodelling of the site of infection  
Early on, vascular endothelial growth factor (VEGF) mediates substantial 
vascularisation of the structure (Alatas et al., 2004). The vasculature has 
extensive lymphocyte cuffing, an indication of cellular recruitment (Figure 
1.4C). Cells found to populate the granuloma include macrophages, 
neutrophils, DCs, T cells, B cells, natural killer (NK) cells and fibroblasts. 
Recently, the epithelial cells surrounding the granuloma have also been shown 
to participate in its formation (Volkman et al., 2010). Progressively, the 
macrophages differentiate into several different morphotypes, including multi-
nucleated giant cells (Helming & Gordon, 2007), epithelioid cells (Adams 
1974), and lipid-rich foamy macrophages (Cáceres et al., 2009) (Figure 1.5). 
At this stage, the stratification of the structure is discernible, a fibrous cuff 
begins to surround the central macrophage zone, excluding majority of the 
lymphocytes from the centre of the granuloma (Figure 1.4D). 
 
The granuloma thus represents an important host-protective structure, where 
the juxtaposition of pathogen-infected antigen-presenting cells and effector T 
cells allow for immune control of mycobacterial infection (Saunders & 
Cooper, 2000).  
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Figure 1.4. Formation of the granuloma. Adapted from “Who puts the 
tubercle in tuberculosis?” by D. G. Russell, 2007, Nature Reviews 
Microbiology	   5(1), pp. 39-47. Copyright 2007 by the Nature Publishing 
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Figure 1.5. Structure and cellular components of the TB granuloma. 
Although granulomas can be composed of many cell types, fundamentally, 
they are defined as compact, well-organised aggregates of mature 
macrophages that are formed in response to persistent stimuli (Williams & 
Williams, 1983). This figure illustrates in detail the different macrophage 
morphotypes in relation to the other cellular components of the granuloma. 
Adapted from “Revisiting the role of the granuloma in tuberculosis” by L. 
Ramakrishnan, 2012, Cell 136(1), pp. 37-49. Copyright 2012 by Cell Press. 
Adapted with permission. 
 
1.6.4.  Heterogeneity in granuloma morphology  
It was already observed in human necropsies more than 60 years ago that 
granuloma morphology was heterogeneous (MEDLAR 1948). Advances in in 
vivo imaging technology coupled with molecular probes to detect host tissue 
metabolism as a yardstick for inflammation now allow monitoring of the same 
granuloma over time, and has shed some light on how the heterogeneity of TB 
lesions may be linked to differences in pathogenesis and responsiveness to 
treatment (Barry et al., 2009; Park, Ryu, & Shim, 2008). In humans and non-
human primates, a range of granuloma types is observed in both active TB and 
Chapter 1: General Introduction 
 24 
latent infection, even in the same individual (Ulrichs et al., 2005; Lin et al., 
2009).  
 
The classic tuberculous granuloma, found in active disease and latent 
infection, has a central necrotic or “caseous” core that arises from the death of 
participating cells (Hunter 2011; Tsai et al., 2006). It is composed of 
epithelioid macrophages, neutrophils, a cuff of lymphocytes and an outermost 
rim of peripheral fibrosis. M. tuberculosis in this granuloma is exposed to 
differing microenvironments in the hypoxic caseum or in the fibrotic rim.  
Apart from humans, hypoxic granulomas have also been reported in rabbits, 
guinea pigs and non-human primate models of TB (Via et al., 2008) but not in 
the standard C57BL/6 or BALB/c mouse models (2008; Tsai et al., 2006).  
 
Non-necrotizing granulomas are more common in active disease and consist 
mainly of macrophages with some lymphocytic infiltrate. M. tuberculosis is 
contained within the macrophages. Mice can reproduce this type of 
granulomas but with more lymphocytes. Fibrotic granulomas are mostly 
observed in latent infection but can also manifest in active TB. These are 
composed almost exclusively of fibroblasts, with a small proportion of 
macrophages. Although it is possible to culture M. tuberculosis from some 
fibrotic lesions, the location and microenvironment of the bacilli remain 
unknown (Dannenberg, 2006) (Figure 1.6). 
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Figure 1.6. Heterogeneity of granuloma morphology. (A) Classic caseous 
granuloma (B) Non-necrotizing granulomas are usually seen in active disease 
and consist mainly of macrophages and some lymphocytes. (C) Fibrotic 
granulomas are seen mostly in latent infection but also in active TB and are 
composed almost completely of fibroblasts, with a small proportion of 
macrophages. Adapted from “The spectrum of latent tuberculosis: rethinking 
the biology and intervention strategies” by C. E. Barry et al., 2009, Nature 
Reviews Microbiology 7(12), pp. 845-855. Copyright 2009 by the Nature 
Publishing Group. Adapted with permission. 
 
1.6.5.  Collapse of the granuloma 
In this balanced, dynamic state, each granuloma contains the infection within a 
discrete “stable unit”, that in most immunocompetent individuals, can resolve. 
However, excessive necrotic cell death and accumulation of caseum in the 
centre of the granuloma ultimately leads to its liquefaction and cavitation, 
releasing live, virulent bacilli into the airways (Kaplan et al., 2003) (Figure 
1.4E). Tissue damage in the lungs triggers a productive cough, which 
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facilitates disease transmission via the generation of infectious aerosols 
(Figure 1.4F). 
 
1.6.6.  Extracellular life of M. tuberculosis within the granuloma 
M. tuberculosis has also been found to persist extracellularly within the 
granuloma. When faced with hypoxia, nutrient starvation, low pH and low 
concentrations of nitric oxide within the granuloma, it is believed that the 
long-term survival of M. tuberculosis is enabled by its transition into a non-
replicating, dormant state mediated by the up-regulation of genes of the 
dormancy survival (dos) regulon, which also controls reversal to replication 
upon re-exposure to oxygen (Gengenbacher & Kaufmann, 2012). This is 
consistent with reports that viable bacilli can be isolated from incidental TB 
lesions of latent individuals post-mortem (Chan & Flynn, 2004). Using an in 
vivo mouse model of artificial granuloma formation, Karakousis and 
colleagues have revealed that the dormancy phenotype of extracellular M. 
tuberculosis within host granulomas may be immune-mediated and IFNγ-
dependent (Karakousis et al., 2004).  
 
Recent evidence suggests that the granuloma may also be manipulated by 
mycobacteria to promote proliferation and dissemination. In a zebrafish model 
of M. marinum infection that enables the visualization of the cellular events of 
granuloma formation at the whole-animal level, it was found that the rapid 
mycobacterial growth phase was associated with granuloma formation, instead 
of preceding it. Furthermore, the absence of the ESAT-6 secretion system 1 
(ESX-1) that is linked to virulence in mycobacteria gave rise to poor 
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granuloma formation (Volkman et al., 2010; Volkman et al., 2004). M. 
tuberculosis residing within pulmonary granulomas thus represents an 
important reservoir of persistent, viable organisms during latent TB infection. 
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1.7.  Adaptive immunity to tuberculosis 
1.7.1. Acquired cellular immunity to TB is T cell-dominated 
1.7.1.1.  CD4+ Th 1 cells are the predominant protective T cell subset   
There is overwhelming evidence that CD4+, major histocompatibility complex 
(MHC) class II-expressing T cells play a major role in protective immunity to 
TB. Control of bacterial growth is severely impaired in CD4+ T cell-deficient 
mice, which rapidly succumb to infection (Cooper 2009b; Saunders, Frank, 
Orme, & Cooper, 2002; Scanga et al., 2000; Caruso et al., 1999), and HIV-
infected patients with CD4+ T cell lymphopenia are highly susceptible to TB 
(Havlir & Barnes, 1999). The protective effector functions of CD4+ T cells are 
largely mediated by their secretion of T helper 1 (Th1) cytokines, most 
importantly, IFNγ. The arrival of IFNγ-secreting, activated CD4+ T cells is 
concomitant with the end of the mycobacterial replicative phase and formation 
of a “stable” granuloma that is responsible for containing the infection during 
latency (Tully et al., 2005; Jung, Ryan, LaCourse, & North, 2005; Fenhalls et 
al., 2002; Chackerian, Perera, & Behar, 2001), during which the bacteria load 
remains low and relatively constant (Muñoz-Elías et al., 2005) and the host 
does not display any overt signs of disease. Recently, it was shown that IFNγ 
from CD4+ T cells is not only required for control of bacterial burden by 
activating macrophage-mediated killing activity, it is also needed to sustain a 
robust CD8+ T cell response (Green, Difazio, & Flynn, 2013). 
 
1.7.1.2.  CD8+ Th 1 cells may play a role in immune surveillance 
In comparision, the lack of CD8+, MHC class I-expressing T cells had little 
impact on disease progression after low-dose aerosol infection (Mogues, 
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Goodrich, Ryan, LaCourse, & North, 2001). However, the adoptive transfer of 
CD8+ T-cells has been shown to be more effective than that of CD4+ T cells in 
protecting against high-dose infection (Orme 1987).  Like CD4+ T cells, CD8+ 
T cells have been shown to secrete IFNγ (Serbina & Flynn, 1999). M. 
tuberculosis antigen-specific CD8+ T cells recruited to the lungs also secrete 
perforin and induce lysis of infected cells (Kamath et al., 2004; Serbina, Liu, 
Scanga, & Flynn, 2000). In addition, it was demonstrated in vitro that CD8+ T 
cells recognise M. tuberculosis-antigens generated by cross priming (Winau et 
al., 2006). CD8+ T cells appear to increase in importance later once bacillary 
growth has stabilised, in the context of immune surveillance (Woodworth & 
Behar, 2006). 
 
1.7.1.3.  Th2, Th17 and Treg cells 
Th2 cells secrete interleukin (IL)-4, IL-5, IL-6, IL-10 and IL-13, and their 
significance during mycobacterial infection is unclear. The Th2 response 
emerges during the chronic phase of the disease (Hernández-Pando et al., 
1996) and may act to down-regulate the Th1 response and limit the extent of 
macrophage-induced pathology, although at the same time it promotes 
persistence of the infection and risk of reactivation (Wangoo et al., 2001; 
Howard & Zwilling, 1999).  
 
More recently, Th17 cells that produce IL-17 and IL-22 have been implicated 
in the immune response to M. tuberculosis infection in humans and mice 
(Khader & Cooper, 2008). In infected mice, IL-17 production is modulated by 
IL-23 (Khader et al., 2005). IL-17 is produced mainly by γδ T cells, a lineage 
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of T cells that are neither CD4+ nor CD8+ (Lockhart, Green, & Flynn, 2006), 
although a distinct IL-17-producing subset of CD4+ T cells has also been 
discovered. The IL-17-producing CD4+ T cell subset and IL-22-producing 
CD4+ T cell subsets are distinct from each other and from Th1 cytokine-
producing cells, and exhibit the phenotypic characteristics of long-lived 
central memory lymphocytes (Scriba et al., 2008). 
 
CD4+ FoxP3+ regulatory T (Treg) cells secrete transforming growth factor 
(TGF)-beta (TGFβ) and IL-10. To date, studies have found either no role for 
Treg cells in the control of mycobacterial infection (Quinn et al., 2008; Quinn 
et al., 2006) or a merely transient one—whereby depletion of Treg cells was 
shown to reduce bacterial burden at early time points post-infection (Ozeki et 
al., 2010). 
 
1.7.2.  Key cytokines balance the immune response between bacterial 
eradication and host survival 
1.7.2.1.  TNF 
TNF is produced by a variety of immune cells, including macrophages, 
neutrophils, DCs, and T cells (Vassalli 1992), and is critical for granuloma 
formation and maintenance. Studies have shown that TNF−/− mice are more 
susceptible to M. tuberculosis infection and granulomas in these mice do not 
form properly (Bean et al., 1999, Flynn et al., 1995). Neutralisation of TNF 
causes reactivation of infection in mice and macaques, proving that TNF is 
essential in the containment of persistent TB (Lin et al., 2010; Chakravarty et 
al., 2008; Botha & Ryffel, 2003).  In the M. marinum-infected zebrafish 
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model, the absence of TNF accelerates bacterial growth within macrophages 
that precedes the necrosis of overladen cells and collapse of the granuloma 
(Clay, Volkman, & Ramakrishnan, 2008).  Apart from being an important 
signal for macrophage activation and intracellular killing of bacilli (2008; 
Flesch & Kaufmann, 1990), TNF also mediates apoptosis of infected 
macrophages, at least in vitro (Keane et al., 2000). Nonetheless, while TNF is 
needed to drive protective granuloma formation, in excess, it can lead to overt 
tissue damage (Casadevall & Pirofski, 2003). 
 
1.7.2.2.  IL-12 and IFNγ  
IL-12, which is mainly secreted by M. tuberculosis-activated DCs, is 
necessary essentially for DC migration and T cell priming induction, and 
maintenance of protective IFNγ T cell responses in early-stage and chronic M. 
tuberculosis infection (Khader et al., 2006; Feng et al., 2005; Cooper, 
Magram, Ferrante, & Orme, 1997).  
 
The IFNγ signalling axis is crucial for resistance to M. tuberculosis, and mice 
lacking IFNγ, IFNγ receptor, or STAT1 are highly susceptible to infection 
((Cooper & Khader, 2008); (Cooper et al., 1993); (Flynn et al., 1993)). As 
discussed previously, IFNγ is critical for the control of M. tuberculosis 
infection via macrophage activation (Herbst et al., 2011). It is known to 
regulate broad transcriptional programs and induce the expression of a variety 
of cytokines and other soluble factors (Boehm, Klamp, Groot, & Howard, 
1997), but the mechanisms downstream of IFNγ signalling responsible for its 
anti-mycobacterial effects are still not completely understood. IFNγ-inducible 
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molecules that have been implicated in the host immune response to M. 
tuberculosis infection include inducible nitric oxide synthase (iNOS) (Herbst 
et al., 2011) and the IFN-inducible guanosine-5'-triphosphate (GTP)-binding 
protein LRG-47 (or lrgm1) (MacMicking, Taylor, & McKinney, 2003). IFNγ 
is also important for phagosome maturation and production of antimicrobial 
peptides (Fabri et al., 2011). Bearing in mind its protective role, it is 
interesting that IFNγ levels were found elevated in the BALF (Tsao et al., 
2002) and serum (Vankayalapati et al., 2003) of patients with active or severe 
TB disease. IFNγ may also have a protective anti-inflammatory role, as 
suggested by its blockade of IL-17 production (Cruz et al., 2006), and its 
direct suppression of neutrophil accumulation in infected lungs and 
impairment of neutrophil survival. Regulation of neutrophils is important 
because their accumulation is detrimental to the host (Nandi & Behar, 2011). 
 
1.7.2.3.  IL-10  
IL-10 is produced by a variety of immune cells including macrophages, 
neutrophils, DCs, B cells, and T cells (Saraiva & O'Garra, 2010). A major 
mechanism whereby IL-10 achieves its immunosuppressive effects is by 
blocking antigen presentation by macrophages and DCs, and also IL-12 
secretion, thus limiting Th1 responses (Demangel, Bertolino, & Britton, 2002; 
(Fiorentino et al., 1991); (Fiorentino, Zlotnik, Mosmann, Howard, & O'Garra, 
1991)). In addition, IL-10 suppresses macrophage functions such as microbial 
killing and TNF production (O'Leary, O'Sullivan, & Keane, 2011; Bogdan, 
Vodovotz, & Nathan, 1991). IL-10 is elevated in active TB patients ((Almeida 
et al., 2009); (Bonecini-Almeida et al., 2004); (Huard et al., 2003)), and M. 
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tuberculosis-infected IL-10−/− mice show decreased bacterial loads in their 
lungs and spleens (Redford et al., 2010; Higgins et al., 2009), supporting a 
role for IL-10 in restricting host-mediated immunopathology during chronic 
M. tuberculosis infection. 
 
1.7.3.  Possible roles for DCs during chronic infection 
DCs have been found to be present in both human and murine chronic 
granulomas during latent infection (Tsai et al., 2006; Uehira et al., 2002). In 
comparison to macrophages, DCs are inferior at killing intracellular BCG and 
M. tuberculosis (Sinha, Singh, Satchidanandam, & Natarajan, 2006; Buettner 
et al., 2005; Bodnar, Serbina, & Flynn, 2001), highlighting the possibility that 
DCs may potentially act as a long-term survival niche for mycobacteria in 
bactericidal environments like the granuloma. Migratory DCs during M. 
tuberculosis infection express a range of chemokine receptors (León & 
Ardavín, 2008), which clearly modulate their movement (Peters et al., 2001; 
Algood & Flynn, 2004), suggesting that DCs, under the direction of multiple 
chemokine receptors, may continuously migrate in and out of the granuloma, 
acting as a vehicle for mycobacterial dissemination during chronic infection. 
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1.8.  Mouse model of tuberculosis 
1.8.1.  Infection profile of M. tuberculosis in the mouse 
The mouse is the most widely used animal model of M. tuberculosis infection. 
Mice can be infected with low doses of inoculum (50 to 500 CFU) via the 
aerosol route, which mimics the natural route of infection in humans. In the 
low-dose aerosol infection model with M. tuberculosis, the most commonly 
used mouse strains, BALB/c and C57BL/6, develop a progressive chronic 
infection. In the lungs of infected mice, M. tuberculosis initially undergoes a 
phase of exponential growth. Around 21 days post-infection, the 
mycobacterial burden reaches a plateau that coincides with development of the 
adaptive immune response (Basaraba 2008; Orme 2005) (Figure 1.7). A 
steady state or “chronic phase” of infection can be maintained for as long as 
over a year (Rhoades, Frank, & Orme, 1997), and like in humans, control of 
bacillary load is dependent on a strong Th1 immune response. However, in 
human LTBI, the number of mycobacteria is usually undetectable, while the 
chronic phase in mice is characterised by elevated but plateauing bacterial 
load (Figure 1.7).  
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Figure 7. Typical M. tuberculosis infection profile in a mouse model of 
low-dose aerosol infection. (A) Bacterial colonisation of the lung. (B) 
Accumulation of IFNγ-producing cells within the lung is slow but correlates 
with a plateau in bacterial growth. Adapted from “IL-23 and IL-17 in the 
establishment of protective pulmonary CD4+ T cell responses after vaccination 
and during Mycobacterium tuberculosis challenge” by S. A. Khader and A. M. 
Cooper, 2007, Nature Immunology 8(4), pp. 369-377. Copyright 2007 by the 
Nature Publishing Group. Adapted with permission. 
 
1.8.2.  Limitations of the mouse model in recapitulating latency and 
granuloma formation in humans 
While human TB exhibits a heterogeneous pathology that manifests as a 
continuum of lesions reflecting various stages of latent and active disease, the 
mouse model is unable to fully recapitulate the range of latency to active 
disease seen in humans (Apt & Kramnik, 2009; Barry et al., 2009; Flynn 
2006; Fortin, Abel, Casanova, & Gros, 2007; Medina & North, 1998). Firstly, 
all mice will ultimately die of progressive infection (Cardona et al., 2000). 
Secondly, murine granulomas do not share the distinctive stratified 
organisation of human granulomas and are exclusively cellular, without 
fibrosis or hypoxia (Via et al., 2008). 
 
1.8.3.  Advantages of the mouse model in studying host immune factors 
Some of the main advantages of the mouse model over other small animal 
models (eg. guinea pig, rabbit and rat) or non-human primate models (eg. 
macaques) are the relatively small size, availability and low cost of laboratory 
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mice, an abundance of immunological tools and reagents, as well as its 
potential for manipulation and the availability of inbred genetically-modified 
strains (Orme 2003). 
 
Although the mouse may not represent an ideal model for latent or persistent 
TB, it is nonetheless an invaluable model for elucidating the roles of host 
factors in protective immunity to TB. Genetic knockout or depletion models of 
mice have shown, for example, that IL-12 (Cooper et al., 1997), IFNγ (Flynn 
et al., 1993), TNF (1995) and CD4+ T cells (Cooper 2009a) are critical 
immune players, and these findings have been validated in human disease 
studies (Alcaïs et al., 2010; Geldmacher et al., 2010; Geldmacher et al., 2008; 
Alcaïs, Fieschi, Abel, & Casanova, 2005; Keane et al., 2001). Moreover, as 
alternatives to the more resistant BALB/c and C57BL/6 strains, highly 
susceptible mouse strains such as CBA/J, DBA/2 and C3H have been 
developed that form lung lesions that more closely resemble those in humans 
(Harper et al., 2012; Apt & Kramnik, 2009; Marquis et al., 2008; Chackerian 
& Behar, 2003). Intra-vital microscopy techniques have revealed that mouse 
TB granulomas are also dynamic structures (Egen et al., 2011).  A novel 
granuloma transplantation approach has the potential to yield important 
insights on the relationship between systemic immunity and mycobacteria-
containing granulomas (Harding, Schreiber, & Sandor, 2011). 
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1.9.  General objectives and significance of this Thesis 
The limited protective efficacy of BCG (McShane 2011) and emergence of 
drug-resistant strains (Gandhi et al., 2010), compounded by synergistic co-
infection with HIV (Pawlowski, Jansson, Sköld, Rottenberg, & Källenius, 
2012) and slow progress in the development of new therapies and vaccines, 
are some of the key challenges presented by the TB epidemic that need to be 
overcome. Efforts to discover novel drugs have largely been focused on 
targeting the bacterium directly. Alternatively, manipulating the host response 
to TB infection may represent a valuable approach to help the host immune 
system clear the bacilli more effectively and more rapidly (Kaufmann et al., 
2014; Young, Perkins, Duncan, & Barry, 2008). Such an approach necessitates 
a deeper understanding of the immune mechanisms associated with protection 
against TB. 
 
With this in mind, we embarked on studying two aspects of host immunity to 
M. tuberculosis infection: the role of Annexin A1, a protein expressed 
endogenously by a variety of immune cells, and the role of the CLEC9A+ DC 
subset, which includes CD103+ migratory DCs in the lung and CD8+ DCs in 
the lymphoid organs. Additional literature and project aims specific to each 
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2.1.  Microbiology 
2.1.1.  Biosafety 
All experiments involving the handling of live M. tuberculosis were 
performed in a Biosafety Level (BSL) 3 laboratory managed by the Defense 
Science Organisation (DSO) National Laboratories, in accordance to Standard 
Operating Procedures (SOPs) approved by the respective Institutional 
Biosafety Committees (IBC) of the National University of Singapore (NUS) 
and DSO National Laboratories. 
 
2.1.2.  Mycobacterial strains 
For the work described in Chapter 3, wild-type (WT) M. tuberculosis 
CDC1551, a kind gift from Novartis Institute of Tropical Diseases, was used. 
This clinical strain was first isolated in 1995, during an outbreak in the United 
States in a rural area considered to be at low risk for TB (Valway et al., 1998). 
CDC1551 has been reported to induce a more robust host immune response, 
although it exhibits similar growth rates both in vitro and in vivo as the 
laboratory strain H37Rv (Manca et al., 1999). For the work described in 
Chapter 4, WT M. tuberculosis H37Rv or green fluorescent protein (GFP)-
expressing M. tuberculosis H37Rv strains were used. The latter was generated 
by transforming the bacteria with peGFP followed by selection of successful 
transformants with kanamycin (20µg/ml). The episomal replicative peGFP 
vector that had been generated by cloning the eGFP-N1 fragment (Clontech) 
into pMV261 after the mycobacterium heat shock protein (hsp) 60 promoter 
was a kind gift from Dr. Seah Geok Teng, NUS.  
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2.1.3.  Mycobacterial culture 
Bacteria were grown in Middlebrook (Difco) 7H9 medium supplemented with 
10% ADS (50g bovine fraction V albumin, 20g D-(+)-glucose and 8.1g NaCl 
per litre), 0.05% Tween-80 and 0.5% glycerol, or on Middlebrook 7H11 agar 
supplemented with 10% OADC (BD Bioscience), 0.5% glycerol, 20µg/ml 
ampicillin (Sigma-Aldrich) and 100µg/ml cyclohexamide (Sigma-Aldrich). 
Cultures were incubated at 37oC with 5% CO2. For the preparation of M. 
tuberculosis stocks, liquid cultures at log phase growth (i. e. the optical 
density at 600nm (OD600) was 0.6 to 0.8) were re-suspended in 7H9 media 
containing 25% glycerol, at a concentration estimated by an OD600 of 1. To 
minimize the number of passages, each batch of stock prepared was aliquoted 
into cryovials of 1ml and frozen at -80oC. A new vial was thawed for each 
experiment. CFU of stocks was initially determined by plating a range of 
dilutions on 7H11 agar plates. After 16 to 21 days incubation at 37°C with 
CO2, the number of CFU was enumerated. Heat-killed mycobacterial 
suspensions were prepared by re-suspending bacterial pellets in phosphate-
buffered saline (PBS) followed by incubation at 90oC for 30min.  
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2.2.  Animal Work 
2.2.1.  Bioethics 
All procedures involving the care and use of animals were approved by the 
respective Institutional Animal Care and Use Committees (IACUC) of NUS 
(protocols 109-09, 094-10 and 073-10) and DSO National Laboratories 
(protocols 10-103 and 10-104). 
 
2.2.2.  Mouse strains  
Adult (six to eight weeks old) mice were bred and maintained in specific 
pathogen-free (SPF) conditions. As far as possible, mice from control and 
experimental groups were age and sex-matched. All WT BALB/c mice were 
obtained from NUS Centre for Animal Resources (CARE). For the work 
described in Chapter 3, ANXA1−/− BALB/c mice were bred by our 
collaborator from NUS, Associate Professor Lina Lim. For the work described 
in Chapter 4, a CLEC9A-human diphtheria toxin receptor (CLEC9A-DTR) 
transgenic line in the BALB/c background was generated by our collaborator 
from Nanyang Technological University (NTU), Associate Professsor 
Christiane Ruedl. 
 
2.2.3.  Infection of live animals  
The inoculum was prepared by serially diluting one freshly thawed vial of M. 
tuberculosis stock to the appropriate concentration in PBS with 0.05% Tween-
20. Animals were anaesthetised by intra-peritoneal injection of a cocktail 
containing 7.5mg/ml ketamine and 0.1mg/ml medetomidine. Anaesthetised 
animals were infected intra-tracheally using a non-invasive technique as 
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described by Singhal and colleagues, which has proven to be precise and 
consistent (Singhal et al., 2010). In brief, a blunted, plastic needle was passed 
through the mouth and the trachea and the inoculum was deposited directly at 
the carina, the sternal angle of the bronchi. For the work described in Chapter 
3, mice were infected with 500 CFU of WT M. tuberculosis CDC1551. For 
the work described in Chapter 4, mice were infected with 500 CFU of WT M. 
tuberculosis H37Rv, or 2000 CFU of GFP-expressing M. tuberculosis H37Rv.  
 
2.2.4.  DT treatment  
CLEC9A-DTR mice subjected to diphtheria toxin (DT) treatment were first 
injected intra-peritoneally with DT (10ng/g of body weight; Sigma-Aldrich) 
diluted in PBS containing 1% serum from uninfected BALB/c mice one day 
(or at least 20 hours) prior to infection, and subsequently every four to five 
days in order to maintain the selective depletion of CLEC9A+ cells. In the 
control group, CLEC9A-DTR mice were injected with diluent only. 
 
2.2.5.  Collection of BALF 
Animals were euthanized at the indicated time points post-infection and 
broncho-alveolar lavage fluid (BALF) was collected by injecting and then 
retrieving 1ml of PBS through an 18G needle inserted into the trachea.  
 
2.2.6.  Processing of organs for quantification of bacterial load in vivo 
Infected animals were euthanized at the indicated time points post-infection. 
Lungs, spleens and/or mediastinal LN (lung-draining) were harvested. Lungs 
and spleens were cut into small pieces and incubated with 1mg/ml collagenase 
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D (Roche, Penzberg, Germany) diluted in Iscove’s modified Dulbecco’s 
medium (IMDM) supplemented with 2% heat-inactivated fetal bovine serum 
(FBS) for 1h (lungs) or 30min (spleens) at 37ºC, under constant agitation. LN 
and collagenase-digested lung and spleen tissues were passed through a 70µm 
cell strainer (Fisher Scientific) to obtain single cell suspensions. For 
quantification of bacterial load, the single cell suspensions were plated neat or 
after the appropriate serial dilutions onto 7H11 agar plates. After 16 to 21 days 
incubation at 37°C with CO2, the number of CFU was enumerated.  
 
2.2.7.  Histology  
Harvested lungs and spleens were immediately fixed in 4% paraformaldehyde 
solution for 24h, then paraffin-embedded and processed for histology. 
Sections (5µm) were stained with hematoxylin and eosin (H&E) and 
histological analysis was performed on blinded samples. Representative 
photographs of sections were taken using a Zeiss Axiovert 40 inverted 
microscope (Zeiss).  
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2.3.  Cell Biology 
2.3.1.  Preparation and culture of BMMΦs  
Bone marrow-derived macrophages (BMMΦs) from uninfected mice were 
generated using a protocol modified from the one described by Zhang and 
colleagues (Zhang, Goncalves, & Mosser, 2008). Bone marrow cells were 
isolated from the femurs of six to eight weeks old BALB/c mice and 
differentiated into resting macrophages in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% heat-inactivated FBS, 100mM 
sodium pyruvate, 1M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) and 100U/ml penicillin, 100µg/ml streptomycin (all from Gibco) 
and 10ng/ml recombinant murine macrophage colony stimulating factor (M-
CSF; Sigma-Aldrich). Differentiated macrophages were recovered in cold 
PBS containing 1mM ethylenediaminetetraacetic acid (EDTA) pH 7.4, and 
then washed once in PBS. Flow cytometry analysis determined that F4/80+ 
cells consistently represented approximately 70 to 80% of the population 
obtained after six days of differentiation. To obtain activated macrophages, the 
culture media was supplemented with 5% horse serum (Sigma-Aldrich) and 
after differentiation the macrophages were activated with 100U/ml 
recombinant murine IFNγ (Sigma-Aldrich) 24h prior to infection.  
 
2.3.2.  Preparation and culture of BMDCs 
Bone marrow-derived dendritic cells (BMDCs) from uninfected mice were 
generated using a protocol modified from the one described by Lutz and 
colleagues (Lutz et al., 1999). Bone marrow cells were isolated from the 
femurs of six to eight weeks old BALB/c mice and differentiated into 
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dendritic cells in RPMI-1640 medium supplemented with 10% heat-
inactivated FBS, 1mM sodium pyruvate, 100U/ml penicillin, 100µg/ml 
streptomycin, 50µM 2-mercaptoethanol (all from Gibco) and 200U/ml 
recombinant murine granulocyte macrophage colony stimulating factor (GM-
CSF; Sigma-Aldrich). Flow cytometry analysis determined that CD11c+ cells 
consistently represented approximately 70 to 80% of the population obtained 
after eight days of differentiation. 
 
2.3.3.  Isolation and culture of primary splenocytes  
Whole spleens were harvested from uninfected mice and gently mashed 
through a 70µm cell strainer using a syringe plunger. Red blood cells were 
lysed in a buffer containing 0.15M NaCl, 1mM KHCO3 and 0.1mM Na-
EDTA (pH 7.2 to 7.4), after which the remaining splenocytes were washed 
and cultured in RPMI-1640 medium supplemented with 10% heat-inactivated 
FBS. 
 
2.3.4.  Infection of BMMΦs for quantification of bacterial load in vitro  
BMMΦs were seeded overnight as a monolayer at 5 x104 cells/well in a 24-
well tissue culture plate. The inoculum was prepared by serially diluting one 
freshly thawed vial of M. tuberculosis stock to the appropriate concentration 
in BMMΦ culture media without antibiotics and FBS. The cells were 
incubated with M. tuberculosis at a multiplicity of infection (MOI) of 2 for 
45min at 37oC in BMMΦ culture media without antibiotics and FBS. 
Subsequently, the cells were washed twice with PBS to remove non-
internalised bacteria, and then incubated for up to six days post-
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culture media with FBS but in the absence of penicillin and streptomycin. At 
the specified time points, the infected cells were washed once with PBS and 
lysed with 0.1% Triton X-100 (Sigma-Aldrich) to release the intracellular 
bacteria. Serial dilutions of the lysates were plated on 7H11 agar for 
enumeration of CFU after 16 days of incubation. 
 
2.3.5.  Infection of BMDCs and splenocytes for quantification of cytokine 
production in vitro 
BMDC or splenocyte cultures prepared from uninfected mice (refer to 
Sections 2.3.2 and 2.3.3) were seeded at 1 x106 cells/well in a 6-well plate 
overnight. Cells were incubated with M. tuberculosis at an MOI of 1 or 5, or 
1µg/ml lipopolysaccharide (LPS) in antibiotic-free culture media for 24h, after 
which the cell culture supernatants were collected and frozen at –80°C until 
analysis. 
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2.4.  Immunology 
2.4.1.  Cytokine quantification 
Cytokines present in BALF samples or cell culture supernatants were analysed 
either by multiplex ELISA (kit from BioRad) or regular ELISA (kits from 
eBioscience) according to the manufacturer’s instructions. Cytokines 
measured include IFNγ, TNF, IL-10 and IL-6. All M. tuberculosis-infected 
samples to be transferred out of the BSL 3 laboratory for cytokine analysis 
were passed through a 0.22µm filter twice. 
 
2.4.2.  Allogeneic mixed lymphocyte reaction 
BMDCs were prepared from uninfected BALB/c mice as described in Section 
2.3.2. T cells were isolated from naïve C57BL/6 mouse spleen preparations 
using a Pan T-cell isolation kit (Miltenyi). BMDCs were infected overnight 
with M. tuberculosis (MOI of 5) in BMDC culture media without antibiotics, 
washed and then co-cultured with T cells at a ratio of 1:5 (BMDC : T cell) for 
four days in RPMI-1640 medium supplemented with 10% heat-inactivated 
FBS. T cell activation was measured by quantifying the IFNγ concentration in 
the supernatant by ELISA (eBioscience). 
 
2.4.3.  Preparation of samples for flow cytometry  
Mouse lungs, spleens and/or mediastinal LN were prepared as described in 
Section 2.2.6. Additionally, red blood cells were lysed (refer to Section 2.3.3), 
washed once and re-suspended in staining buffer (PBS with 5% heat-
inactivated FBS). Samples were passed through a 70µm cell strainer one more 
time to remove any clumps and to obtain a homogenous single cell 
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suspension. Samples from in vitro experiments, such as BMMΦ and BMDC 
cultures (Chapter 3) or re-stimulated lungs and LN (Chapter 4) were washed 
once to remove any residual culture media and re-suspended in staining 
buffer.  
 
Cell suspensions were transferred to a v-bottom 96-well plate for subsequent 
staining procedures. Staining buffer was used for all the necessary wash steps 
and for the dilution of antibodies for extracellular staining. Samples were 
blocked with anti-CD16/32 antibody for 10min at room temperature and then 
surface stained by incubation with the appropriate fluorescent antibodies in the 
dark for 30min at 4°C. After extracellular staining, all samples handled in the 
BSL 3 laboratory were fixed in 2% paraformaldehyde diluted in PBS for 24h 
before subsequent steps including intracellular staining and data acquisition by 
flow cytometry was conducted in a BSL 2 laboratory.  
 
Data acquisition was performed using an LSRII Fortessa flow cytometer and 
FACS Diva software (BD Biosciences), or a FACS Cyan flow cytometer and 
Summit software (Beckman Coulter). The data was analyzed using FlowJo 
software (Version 9.3.1). A live/dead fixable dye in the far-red fluorescent 
spectrum, APC-Cy7 (Invitrogen), was included in the antibody mix for gating 
on live cells. Antibodies used are listed in Table 2.1. 
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Table 2.1. Antibodies  
 
Surface marker Clone Fluorophore Source 
B220 (CD45R) RA3-6B2 N.A. (Biotin) eBioscience 
CCR5 HM-CCR5 (7A4) PE eBioscience 
CCR7 4B12  APC eBioscience 
CD11b M1/70 PB eBioscience 
CD11b M1/70 PerCP-Cy5.5 eBioscience 
CD11c N418 PE eBioscience 
CD4 RM4-5 APC eBioscience 
CD4 RM4-5 eFluor®450 eBioscience 
CD8 53-6.7 FITC eBioscience 
CD44 IM7 PE Bio Legend 
CD62L MEL-14 APC BD Pharmingen 
CD69 H1.2F3 PE eBioscience 
CD45 30-F11 APC-Cy7 eBioscience 
CD80 16-10A1  PE eBioscience 
CD86 GL1 APC eBioscience 
CD103 2E7 APC eBioscience 
F4/80 BM8 APC eBioscience 
F4/80 BM8 PE eBioscience 
IFNγ XMG1.2 APC eBioscience 
MHCII (IA/IE) 2G9 eFluor®450 eBioscience 
MHCII (IA/IE) 2G9 PerCP-eFluor®710 eBioscience 
Siglec 551 PE eBioscience 
N.A. (Streptavidin) N.A. APC-Cy7 eBioscience 
 
Note. All antibodies are anti-mouse. N.A., not applicable. 
 
2.4.4.  T cell re-stimulation  
Single cell suspensions were prepared from the lungs and mediastinal LN as 
described in Section 2.2.6 and re-suspended in IMDM supplemented with 
10% heat-inactivated FBS for culture. The cells were incubated at 37°C with 
CO2 for 18h with 10µg/ml tuberculin PPD (Statens Serum Institut) or 4h with 
a T cell-mitogenic cocktail comprising of 10-5M phorbol 12-myristate 13-
acetate (PMA; Sigma-Aldrich) and 1µg/ml ionomycin (Sigma-Aldrich). In the 
final 4h of incubation, 10µg/ml Brefeldin A (Sigma-Aldrich) was added to the 
cultures. After the period of re-stimulation in vitro, the samples were prepared 
for flow cytometry as described in Section 2.4.3. Additionally, intracellular 
staining for IFNγ was performed. Fixed cells were washed twice in 
permeabilisation buffer (staining buffer with 0.1% saponin), resuspended in 
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permeabilisation buffer containing diluted APC-conjugated IFNγ and 
incubated in the dark for 30min at room temperature. Cells were then washed 
once again with permeabilisation buffer and finally once with staining buffer 
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2.5.  Statistical analysis 
Data were analysed on Prism 5.0 software (GraphPad) and the Student t-test 
was used to determine statistical significance between two matched groups. 
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3.1.  Introduction 
3.1.1. ANXA1 and its receptor are expressed on immune cells 
Annexin A1 (ANXA1), formerly known as lipocortin-1, is a 37kDa member 
of a superfamily of calcium and phospholipid-binding proteins, and signals by 
binding to a G-protein-coupled receptor (GPCR), ALXR, which is also the 
receptor for the anti-inflammatory molecule lipoxin A4 (Perretti et al., 2002). 
Human ALXR belongs to a family of formyl peptide receptors (FPRs) 
comprising of three members (FPR1, FPR2 or ALXR, and FPR3) (Perretti, 
Getting, Solito, Murphy, & Gao, 2001; Walther, Riehemann, & Gerke, 2000). 
Both ANXA1 and ALXR/FPR2 are expressed by a variety of cell types, 
including endothelial cells and epithelial cells, and immune cells such as 
macrophages, DCs, T cells and neutrophils; however, it has not been detected 
in B cells (Rescher & Gerke, 2004; Perretti et al., 2000). In resting conditions, 
human and mouse neutrophils, macrophages and DCs constitutively express 
high levels of endogenous ANXA1 in their cytoplasm which can be mobilized 
to the cell surface and secreted in a cell-specific response to activation 
(Huggins, Paschalidis, Flower, Perretti, & D'Acquisto, 2009; Rescher & 
Gerke, 2004; Perretti et al., 2000). Naïve T cells express 100-fold less 
ANXA1 than myeloid cells and negligible levels of FPR2, but upregulate the 
ANXA1-FPR2 pathway following activation and differentiation (D'Acquisto 
et al., 2007a; D'Acquisto et al., 2007b).  
 
Synthetic peptides derived from the N-terminal region of ANXA1 have been 
shown in vitro to also activate FPRs (Dahlgren et al., 2000). However, these 
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bioactive ANXA1 fragments are not naturally present in vivo and are not 
known to have any biological significance. 
 
3.1.2.  Counter-regulatory role of ANXA1 in the inflammatory response  
On the whole, endogenous and exogenous ANXA1 appear to counter-regulate 
the activities of innate immune cells such as neutrophils and monocytes, in 
particular their migration and the generation of pro-inflammatory mediators 
(Côté et al., 2010; Blume et al., 2009; Perretti & Flower, 2004). Multiple 
studies using experimental models of inflammation have shown that 
administration of ANXA1 or ANXA1-derived peptides to mice leads to potent 
inhibition of neutrophil trafficking (2004). The mechanisms behind these in 
vivo observations have also been well documented in vitro; ANXA1 or 
ANXA1-derived peptides have been shown to block neutrophil adhesion to 
and transmigration through endothelial cell monolayers (Walther et al., 2000; 
Zouki, Ouellet, & Filep, 2000). ANXA1−/− mice generally display an 
exacerbated inflammatory response involving increased leukocyte 
transmigration (Chatterjee et al., 2005) and increased expression of 
inflammatory markers (Damazo et al., 2005). ALXR−/− mice have not yet been 
generated; instead, genetic knock-out mouse models of the structurally 
homologous FPR1 have been used to study the effects of ANXA1 in the 
absence of FPR signalling. In an FPR−/− model of peritonitis, inhibition of 
leukocyte migration was partially reduced (Perretti et al., 2001).  
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3.1.3.  ANXA1 expression is modulated by glucocorticoids and in turn 
mediates their anti-inflammatory effects  
In healthy volunteers, blood neutrophils and monocytes were found to up-
regulate ANXA1 expression following glucocorticoid treatment (Goulding et 
al., 1990). Cushing’s disease is associated with high levels of cortisol, a 
naturally occurring glucocorticoid, and leukocytes from patients this disease 
have express higher intracellular levels of ANXA1 than healthy controls. The 
reverse is observed for patients with Addison's disease that is associated with 
low levels of cortisol (Mulla, Leroux, Solito, & Buckingham, 2005). ANXA1 
synthesis is inducible by glucocorticoid treatment in a variety of cell types 
(McLeod, Goodall, Jelic, & Bolton, 1995; Peers, Smillie, Elderfield, & 
Flower, 1993), and recently, the incubation of monocytes with dexamethasone 
was shown to induce the de novo synthesis of ALXR (Sawmynaden & 
Perretti, 2006). In an ANXA1−/− model of acute inflammation, cyclooxygenase-
2 (COX-2) levels were elevated while treatment with the synthetic 
glucocorticoid dexamethasone had no effect compared to controls, suggesting 
that ANXA1 mediates the anti-inflammatory effects of glucocorticoids 
(Hannon et al., 2003). 
 
3.1.4.  Diverse roles for ANXA1 in the regulation of cell proliferation 
ANXA1 can be phosphorylated by a number of kinases. It is thought to exert 
its anti-proliferative effects by activating the mitogen-activated protein kinase 
/extracellular signal-regulated kinases (MAPK/ERK) pathway upon 
phosphorylation by epidermal growth factor receptor tyrosine kinase (EGFR-
TK), leading to disruption of the actin cytoskeleton and the inhibition of cyclin 
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D1 (Hsiang, Tunoda, Whang, Tyson, & Ornstein, 2006; Alldridge & Bryant, 
2003; Alldridge, Harris, Plevin, Hannon, & Bryant, 1999). On the other hand, 
phosphorylation of ANXA1 by protein kinase C (PKC) (Varticovski et al., 
1988), platelet-derived growth factor receptor tyrosine kinase (PDGFR-TK) 
and hepatocyte growth factor receptor tyrosine kinase (HGFR-TK) (Skouteris 
& Schröder, 1996) and transient receptor potential cation channel subfamily M 
member 7 (TRPM7) kinase (Dorovkov & Ryazanov, 2004) has been found to 
enhance proliferation. Some tumour cell lines have been reported to increase 
ANXA1 expression while it is down-regulated in others (Lim & Pervaiz, 
2007). 
 
3.1.5.  Roles of ANXA1 in leukocyte apoptosis 
Three main effects of ANXA1 in leukocyte apoptosis have been reported, 
which suggest that ANXA1 contributes to the resolution of inflammation. 
Firstly, exogenously administered ANXA1 has been found to induce the 
apoptosis of neutrophils via the pro-apoptotic protein BCL-2-antagonist of cell 
death (BAD) (Solito et al., 2003), although glucocorticoid treatment is known 
to inhibit neutrophil apoptosis (Parente & Solito, 2004), which is interesting 
given the relationship between ANXA1 and glucocorticoids as discussed 
earlier. Secondly, neutrophils undergoing apoptosis release endogenous 
ANXA1 which promotes macrophage engulfment of apoptotic cells (Scannell 
et al., 2007) Lastly, ANXA1 secreted by macrophages in response to 
glucocorticoid treatment stimulates the phagocytic clearance of apoptotic 
neutrophils via autocrine or paracrine effects (Maderna, Yona, Perretti, & 
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Godson, 2005). These activities have yet to be confirmed in vivo, and their 
underlying molecular mechanisms are also unclear.  
 
3.1.6.  Role of ANXA1 in adaptive immunity 
Exogenously administered recombinant ANXA1 and its derived peptides have 
been shown to exhibit anti-proliferative activity on mitogen- and antigen-
stimulated T cells (Kamal, Smith, De Silva Wijayasinghe, Solito, & Corrigan, 
2001; Gold, Pepinsky, Zettl, Toyka, & Hartung, 1996), and the data suggest 
that ANXA1 may exert an anti-proliferative effect by specifically interfering 
with the process of antigen presentation. Several studies reveal inherent 
complexities in the actions of ANXA1. In a model of antigen-induced arthritis, 
T cell-expressed ANXA1 was shown to suppress T cell-dependent 
inflammatory responses such as proliferation and Th1/Th17 cytokine 
production (Yang et al., 2004). However, the reduced antigen-specific 
immunoglobulin (Ig) G levels in ANXA1−/− mice raise the intriguing 
possibility that ANXA1 may have a stimulating effect on B cell function and 
humoral immunity. Likewise, in an ovalbumin (OVA)-induced model of 
airway hyper-responsiveness, ANXA1 was associated with attenuation of the 
allergic inflammation (Ng et al., 2011), whereby exacerbated inflammation 
was observed in the ANXA1−/− mice. However, antigen-induced activation of 
MAPK and nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) pathways in the lungs of these animals were reduced. The actions of 
ANXA1 on T cell activation appear to be subset-specific, promoting Th1 and 
Th17-mediated responses while restricting Th2 development  (D'Acquisto et 
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al., 2007a; 2007b). It is also suggested that the actions of ANXA1 could differ 
according to the state of T cell activation (2007b).  
 
3.1.7.  Role of ANXA1 in immunity against infection 
While there have been numerous studies on the role of ANXA1 in acute 
inflammatory disease (Bist et al., 2013; Jorge et al., 2013; Mimura, Tedesco, 
Calabrese, Gil, & Oliani, 2012;  Huggins et al., 2009), far less has been 
reported on the role of ANXA1 in immunity against infection. Specifically, 
Gan and colleagues were the first to report a link between ANXA1 and TB, 
proposing a model in which M. tuberculosis exerts its virulence by 
manipulating the host apoptotic response via ANXA1 (Gan et al., 2008). 
However, the involvement of ANXA1 in vivo was not investigated.  
 
3.1.8.  Specific aims 
Since the early discovery of ANXA1 in the late 1970s (Blackwell et al., 
1980), much of the research in this field has been focused on characterising its 
role in the acute inflammatory response.  Given the known effects of ANXA1 
on neutrophils and macrophages, major host cells of M. tuberculosis, as well 
as T cells, important mediators of the protective immune response to M. 
tuberculosis (Summarised in Figure 3.1), we were prompted to address an 
obvious gap in the current knowledge on the biology of ANXA1, that is, its 
role in chronic infectious disease. Because the effects of ANXA1 may be 
modulated by exogenous administration of synthetic glucocorticoids, both in 
vitro and in vivo, a deeper understanding of the role of ANXA1 in TB may 
pave the way for the identification of novel therapeutic strategies. 
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Here, using an ANXA1−/− mouse model, we aimed to first establish the overall 
in vivo effect of ANXA1 in the context of M. tuberculosis infection by 
documenting the impact of its absence on bacterial burden, pathology and 
critical determinants of protective immunity such as cytokine production.  We 
also examined the effect of ANXA1 on the immunological functions of 
infected immune cells.  
 
 
Figure 3.1. Model of glucocorticoid modulation of the ANXA1 pathway in 
immune regulation. Perretti and D’Acquisto summarise the diverse and 
sometimes conflicting effects of ANXA1 on immune cells, and propose a 
model in which endogenous and synthetic glucocorticoids can control innate 
and adaptive immune responses in the context of inflammation by modulating 
the intracellular expression and extracellular release of ANXA1. The goal of 
this system is to actively maintaining homeostatic control of innate immune 
cells so as to promote the resolution of the inflammation, acknowledging that 
spatial and temporal factors can influence the final outcome. Adapted from 
“Annexin A1 and glucocorticoids as effectors of the resolution of 
inflammation” by M. Perretti and F. D’Acquisto, 2009, Nature Reviews 
Immunology 9, pp. 62-70. Copyright 2009 by the Nature Publishing Group. 
Adapted with permission. 
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3.2. Results 
3.2.1.  Control of bacillary load is transiently impaired in M. tuberculosis-
infected ANXA1−/− mice  
We compared the infection profiles in ANXA1−/− and WT mice following 
intra-tracheal administration of approximately 500 CFU of M. tuberculosis 
CDC1551 strain. The infection profile in the lungs and spleen of M. 
tuberculosis-infected WT and ANXA1−/− mice were comparable up to eight 
weeks post-infection. However, at 12 weeks post-infection, ANXA1−/− mice 
reproducibly displayed a significantly higher bacterial load in both the lungs 
and the spleen compared to the WT control animals. At 16 weeks post-
infection however, the lung bacterial loads were again similar in both infected 
groups (Figure 3.2). 
 
 
Figure 3.2. Infection profile in WT and ANXA1−/− mice. Bacterial loads in 
the lungs (A) and spleens (B) from ANXA−/− or WT mice infected intra-
tracheally with approximately 500 CFU of M. tuberculosis CDC1551. The 
number of CFU was determined by plating appropriate dilutions of organ 
homogenates on 7H11 agar and enumeration after 16 days of incubation. 
Results are expressed as the mean ± SEM (n=4 mice/group). The experiment 
was repeated twice; a representative experiment is shown. *p<0.05. 
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3.2.2.  M. tuberculosis-infected ANXA1−/− mice develop more severe 
granulomatous inflammation in the lungs  
We next investigated whether the differences in bacterial load were associated 
with any differences in pathology.  Early during the infection (up to eight 
weeks post-infection), there were no visible differences in the gross 
morphology of the lungs and spleens from ANXA1−/− mice compared to WT 
mice. Granulomatous structures were equally present in lungs from both 
groups; spleens were similar in size (Figure 3.3A). By 12 weeks post-infection 
however, ANXA1−/− mice displayed visibly larger and more extensive 
granulomatous lesions in the lungs, and developed markedly enlarged spleens 
compared to the WT mice (Figure 3.3A). Histology analysis performed on 
H&E stained sections showed that both M. tuberculosis-infected WT and 
ANXA1−/− lung sections displayed signs of granulomatous inflammation 
characterized by the infiltration and aggregation of lymphocytes and 
histiocytes (macrophages) (Figure 3.3B). However, in the WT group, 
inflammation was limited to vascular-associated focal lesions with most of the 
lung tissue remaining normal with intact alveolar structures, whereas 
inflammation in ANXA1−/− lungs appeared to be disseminated throughout most 
of the organ and accompanied by severe type II pneumocytic hyperplasia. At 
higher magnification (200x), many of the cells in ANXA1−/− lungs appeared to 
be undergoing nuclear pyknosis (chromatin condensation) that precedes 
necrotic nuclear fragmentation, which was not observed in the WT. Highly-
vacuolated or foamy macrophages, a distinct characteristic of lung granulomas 
in experimental mouse models of chronic tuberculosis (Tsai et al., 2006), 
often appeared in clusters and were more prevalent in the ANXA1−/− lung 
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sections than in the WT. In the spleen sections, both groups showed signs of 
inflammation indicated by white pulp expansion, but this was exacerbated in 
the ANXA1−/− mice (Figure 3.3B). 
 
 
Figure 3.3. Histological analysis of lungs and spleens from WT and 
ANXA1−/− M. tuberculosis-infected mice. (A) Gross morphology of lungs and 
spleens from M. tuberculosis-infected ANXA−/− or WT mice harvested at eight, 
12 or 16 weeks post-infection. Samples shown were fixed in 10% PFA. (B) 
H&E-stained lung and spleen sections prepared from samples harvested 16 
weeks post-infection were observed under 50x or 200x objectives. 
Granulomatous inflammation in the WT lungs manifested as distinct lesions 
whereas in the ANXA1−/− lungs the inflammation was disseminated, leading to 
global disruption of the normal lung architecture. The arrow indicates a cluster 
of highly vacuolated or foamy macrophages. For each mouse, three sections 
per organ were viewed and representative fields are shown (n=3 mice/group).  
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3.2.3.  M. tuberculosis-infected ANXA1−/− mice display reduced TNF and 
IFNγ production in the lungs during the early chronic phase of infection  
To investigate the possible mechanisms resulting in the transient higher 
bacterial burden and exacerbated histopathology observed in the ANXA1−/− 
mice, local cytokine levels were quantified in the BALF at various time points 
post-infection, for up to 16 weeks. Significantly lower levels of TNF and IFNγ 
were measured in the BALF from ANXA1−/− mice at five weeks post-infection 
compared to the WT infected animals, preceding any noticeable differences in 
pathology or bacterial load (Figure 3.4).  
 
 
Figure 3.4. Local cytokine profile in the BALF from WT and ANXA1−/− 
M. tuberculosis-infected mice. TNF and IFNγ levels were monitored over 
time in the BALF by ELISA from M. tuberculosis-infected ANXA1−/− or WT 
mice as indicated. Results are expressed as the mean ± SEM (n=5 
mice/group). The experiment was repeated twice; a representative experiment 
is shown. *p<0.05.  
 
  



































Chapter 3: The Role of Annexin A1 in M. tuberculosis Infection 
 62 
3.2.4.  M. tuberculosis-infected ANXA1−/− mice display increased 
infiltration of activated CD4+ and CD8+ T cells in their lungs 
The lower levels in TNF and IFNγ measured in the BALF from ANXA1−/− 
mice early in the chronic phase prompted us to further investigate the status of 
the adaptive immune response in those animals. In particular, the recruitment 
and activation of T cells were monitored over time during M. tuberculosis 
infection of ANXA1−/− versus WT mice. Flow cytometry analysis revealed 
similar numbers of total CD4+ and CD8+ T cells in both WT and ANXA1−/− 
infected lungs from five to 16 weeks post-infection (Figure 3.5A and 3.5C).  
However, the number of activated CD4+ and CD8+ T cells, as indicated by 
CD69 expression, was significantly increased in ANXA1−/− lungs compared to 
WT lungs at 12 weeks post-infection (Figure 3.5B and 3.5D). 
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Figure 3.5. T cell populations in the lungs from WT and ANXA1−/− M. 
tuberculosis-infected mice. At the indicated time points post-infection, single 
cell suspensions were prepared from the lungs of WT and ANXA1−/− M. 
tuberculosis-infected mice and stained for CD45, CD3, CD4, CD8 and CD69 
markers. The total numbers of (A) CD4+ CD8−, (B) CD4+ CD8− CD69+, (C) 
CD8+ CD4−, (D) CD8+ CD4− CD69+ T cells per lung were analysed by flow 
cytometry. Results are expressed as the mean ± SEM (n=5 mice/group). The 
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3.2.5.  Cytokine production, maturation and ability to activate naïve T 
cells is impaired in ANXA1−/− BMDCs 
To gain further knowledge on the mechanisms by which the ANXA1 pathway 
is engaged during M. tuberculosis infection, we examined the impact of 
ANXA1 deletion in vitro on single cell populations. 
 
We first compared the infection profile of M. tuberculosis in WT and 
ANXA1−/− macrophages, the main host cell for this pathogen. It appeared that 
the lack of ANXA1 had no impact on the ability of M. tuberculosis to replicate 
and survive within resting and activated BMMΦ, as evidenced by similar 
infection profiles in both WT and ANXA1−/− BMMΦ (Figure 3.6A and B). 
Furthermore, the levels of TNF produced in the culture supernatants of resting 
ANXA1−/− BMMΦs infected with M. tuberculosis at MOI of 1 or 5, or 
activated with LPS were also similar (Figure 3.6C). 
 
Next, we questioned whether the absence of ANXA1 in DCs would impair 
some of their functions upon M. tuberculosis infection. BMDCs were prepared 
from WT and ANXA1−/− mice and infected with M. tuberculosis. The levels of 
TNF, IL-6 and IL-10 were measured in the cell culture supernatants from 
ANXA1−/− and WT BMDCs at 24h post-infection. Significantly higher levels 
of these three cytokines were detected in the supernatants of ANXA1−/− 
BMDCs compared to the WT controls (Figure 3.7). Interestingly, in contrast 
to BMDCs, significantly lower levels of TNF, IL-6, IL-10 and IFNγ were 
detected in the supernatants of primary ANXA1−/− splenocyte cultures infected 
with M. tuberculosis compared to WT splenocytes (Figure 3.8). This 
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observation thus suggested that cell types other than DCs in the spleen 
contribute to the net production of TNF, IL-6, IL-10 and IFNγ upon M. 
tuberculosis infection in vivo. 
 
Compared to WT BMDCs, ANXA1−/− BMDCs displayed reduced surface up-
regulation of several maturation markers when infected with M. tuberculosis, 
namely CD80, CD86, CD40, MHC class II (MHCII) and CCR7 (Figure 3.9). 
To evaluate the ability of ANXA1−/− BMDCs to prime naïve CD4 T cells, an 
allogeneic mixed lymphocyte reaction (MLR) assay was performed where M. 
tuberculosis-infected BMDCs prepared from WT and ANXA1−/− mice were co-
cultured with naïve WT C57BL/6 T cells. IFNγ production was measured as 
an indicator of T cell activation. The results indicated that T cells incubated 
with M. tuberculosis-infected ANXA1−/− BMDCs produced significantly lower 
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Figure 3.6. Infection profile and TNF production in ANXA1−/− 
macrophages. (A) Resting or (B) IFNγ-activated BMMΦs derived from WT 
and ANXA1−/− mice were infected with M. tuberculosis CDC1551 at MOI of 2 
for 45min at 37oC. Non-internalised bacteria were washed away and the cells 
were incubated for up to six days post-infection. At the specified time points, 
intracellular bacterial loads were quantified by plating whole cell lysates on 
7H11 agar and enumerating the number of CFU after 16 days of incubation. 
Day 0 time point corresponds to the number of CFU internalised after 45min 
co-incubation with the macrophages. Results are expressed as the mean ± 
SEM of quadruplicates. *p<0.05. (C) TNF levels were measured by ELISA in 
the culture supernatant from ANXA1−/− or WT resting BMMΦs infected with 
M. tuberculosis CDC1551 at MOI of 1 or 5, or activated with LPS as indicated 
and incubated for 24h. UI, uninfected. Results are expressed as the mean ± 
SEM of triplicates. The experiment was repeated thrice; a representative 
experiment is shown. *p<0.05. 
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Figure 3.7. Cytokine secretion by M. tuberculosis-infected ANXA1−/− 
dendritic cells. BMDCs derived from WT and ANXA1−/− mice were infected 
with M. tuberculosis CDC1551 at MOI of 1 or 5 as indicated or incubated 
with LPS. The levels of TNF, IL-6 and IL-10 were measured by ELISA in the 
cell culture supernatants from 24h post-infection. Results are expressed as the 
mean ± SEM of triplicates. The experiment was repeated thrice; a 
representative experiment is shown. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 3.8. Cytokine secretion by ANXA1−/− splenocytes infected with M. 
tuberculosis. Single cell suspensions of total splenocytes were prepared from 
the spleens of WT and ANXA1−/− mice. Splenocytes were infected with M. 
tuberculosis CDC1551 at MOI of 1 and incubated for 48h. The levels of TNF, 
IL-6, IL-10 and IFNγ in the cell culture supernatants were measured by 
ELISA. UI, uninfected. Results are expressed as the mean ± SEM of 
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Figure 3.9. Surface expression of maturation markers on ANXA1−/− 
BMDCs infected with M. tuberculosis. BMDCs derived from WT and 
ANXA1−/− mice were inoculated with LPS, heat-killed or live M. tuberculosis 
CDC1551 bacteria at MOI of 1 or 5 as indicated, and incubated for 24h. 
Expression of CD80, CD86, CD40, MHCII and CCR7 markers was 
determined by flow cytometry. Results are expressed as the average MFI ± 
SEM of duplicates. Legend: UI, uninfected control; HK, infected with heat-
killed M. tuberculosis; LPS, positive control; TB, infected with live M. 
tuberculosis; numbers indicate the MOI, i.e. 1 or 5. The experiment was 
repeated twice; a representative experiment is shown. *p<0.05, **p<0.01. 
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Figure 3.10. Allogeneic mixed lymphocyte reaction assay. BMDCs from 
WT and ANXA1−/− mice were infected overnight with M. tuberculosis 
CDC1551 at MOI of 5. The infected BMDCs were then co-cultured for four 
days with naïve WT C57BL/6 T cells at a ratio of 1:5 (BMDC to T cells), and 
IFNγ levels were measured in the culture supernatants by ELISA. Legend: TC 
only, naïve T cells only (without BMDCs); TC(+), T cells stimulated with 
mitogenic cocktail of PDBu and ionomycin; DC only, M.tuberculosis-infected 
BMDCs only (without T cells); DC+TC, un-stimulated BMDCs co-cultured 
with T cells (ratio of 1:5); DC(TB)+TC, M. tuberculosis-infected BMDCs and 
T cells (ratio of 1:5). Results are expressed as the mean ± SEM of triplicates. 
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3.3.  Discussion 
ANXA1 has been shown to exert anti-inflammatory effects in a variety of 
experimental models (Perretti & Dalli, 2009). Recently, Gan and colleagues 
demonstrated in vitro that virulent M. tuberculosis H37Rv is able to prevent 
ANXA1 cross-linking, a requisite for apoptotic envelope formation, via the 
down-regulation of plasminogen activator inhibitor-2 (PAI2) synthesis, and 
that this ability is lost in the attenuated mycobacterial strain counterpart, 
H37Ra. Their in vitro findings collectively suggest that virulent strains of M. 
tuberculosis promote proteolysis of 37kDa ANXA1 into a shorter 34kDa 
fragment that cannot be cross-linked by tissue transglutaminase, leading to 
macrophage necrosis and dissemination of bacilli. Together with their 
observation that WT BALB/c mice infected with H37Rv showed increased 
macrophage necrosis compared to mice infected with H37Ra, the authors 
proposed a model in which M. tuberculosis exerts its virulence by 
manipulating the host response via ANXA1 (Gan et al., 2008). However, this 
study lacked direct experimental evidence of a role for ANXA1 during TB. 
Here, we have used ANXA1-deficient mice to evaluate the impact of the 
absence of ANXA1 on TB infection.  
 
3.3.1.  ANXA1 affects control of bacillary load in vivo  
It is widely documented that ANXA1 is abundantly expressed in leukocytes 
and potently inhibits their trafficking, adhesion and migration to endothelial 
cell layers (Perretti & Dalli, 2009; Perretti et al., 2002; Getting, Flower, & 
Perretti, 1997). Classically, in tuberculosis, the inhaled mycobacteria are first 
taken up by macrophages and transported across the alveolar epithelium into 
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the lung tissue, where granuloma formation is initiated. This localised tissue 
response involves the recruitment of various leukocytes including monocytes 
and macrophages. We hypothesised that ANXA1 may influence the 
accumulation of cells during the development of the granulomatous response, 
and thus also containment of the infection, given its effects on cellular 
mobilisation.  
 
ANXA1−/− mice are viable and do not have a discernible phenotype unless 
challenged with inflammatory stimuli (Damazo et al., 2005; Yang et al., 
2004). In contrast to humans, mice are able to tolerate a relatively high 
bacterial load without any overt symptoms of disease (Ehlers & Schaible, 
2012). In the typical mouse model of pulmonary tuberculosis, bacterial 
multiplication is exponential during the initial “replicative phase”. From about 
three weeks post-infection onwards as cell-mediated immunity develops, the 
animals maintain a “chronic phase” of infection during which constant but 
relatively high number of mycobacteria can be detected in the lungs and other 
organs, instead of the typical “latent infection” described in humans with an 
undetectable level of replicating bacteria (McMurray 2001; Rhoades et al., 
1997). Our data demonstrate that the absence of ANXA1 transiently affects 
the control of the bacterial burden in the lungs during the chronic phase of the 
infection (Figure 3.2). 
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3.3.2.  ANXA1 restrains M. tuberculosis-induced granulomatous 
inflammation in the lungs 
The formation of caseating granulomas is a hallmark of M. tuberculosis 
infection in humans (Saunders & Britton, 2007). These structures classically 
contain concentric layers of various immune cells in an attempt to wall off the 
pathogen and restrict its multiplication. M. tuberculosis-infected WT mice 
develop granulomatous structures but these lesions do not appear as well-
organized as those in humans (Leong et al., 2011). To further study the role of 
ANXA1 in the granulomatous response to tuberculosis, lung histology was 
conducted. The exacerbated granulomatous response observed in ANXA1−/− 
mice (Figure 3.3) not only results in extensive disorganization and destruction 
of the lung tissue but also is likely to impair the ability to control bacterial 
replication. Nonetheless, the transient impact of ANXA1 deletion on bacterial 
load clearly indicates that the microenvironment of the granuloma and its 
control of the bacterial reservoir are modulated by factors beyond the 
influence of ANXA1 on the physical aggregation of cells. 
 
3.3.3. ANXA1 influences the production of TNF and IFNγ in the early 
chronic phase, which affects long term control of M. tuberculosis infection  
The cytokine balance during M. tuberculosis infection is critical in the control 
of mycobacterial growth and maintenance of tissue function (Cooper & 
Khader, 2008). Cytokines such as TNF and IFNγ are essential for the 
induction of cell-mediated immunity and granuloma formation that ultimately 
control the infection (Cruz et al., 2006; Bean et al., 1999). Our data suggest 
that a reduced expression of key cytokines early on at five weeks post-
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infection in the ANXA1−/− mice (Figure 3.4) may have far reaching effects on 
the later development of the disease, potentiating an increase in bacterial 
burden and disorganization of the granulomatous response (Figure 3.3). This 
corroborates with a large body of evidence that cytokine expression is a key 
mechanism by which both pathogen and host may modulate T cell priming as 
well as their effector capabilities, and thus drastically alter the outcome of the 
infection (Cooper & Khader, 2008). 
 
3.3.4.  Increased lung bacterial burden during the late chronic phase in 
ANXA1−/− mice is associated with higher frequencies of activated CD4 and 
CD8 T cells  
We found that the number of activated CD4+ and CD8+ T cells was 
significantly increased in ANXA1−/− lungs compared to the WT at 12 weeks 
post-infection (Figure 3.5B and D), which correlates with the transient 
increase in bacterial load (Figure 3.2) and exacerbated granulomatous 
inflammation (Figure 3.3).  
 
Our in vivo observations thus suggest that the early imbalance of key 
cytokines could explain the failure of ANXA1−/− mice to control the bacterial 
burden later on in the chronic phase. The increased availability of bacterial 
antigens in the lungs may contribute to the activation of infiltrating T cells in 
situ.  
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3.3.5. ANXA1 is involved in the regulation of DC function in terms of 
cytokine production, maturation and T cell activation 
Alveolar macrophages are the first cell population that is encountered by 
mycobacteria upon reaching the lung alveoli. The ability of M. tuberculosis to 
establish infection in resting and to a lesser extent in activated macrophages 
has been well studied (van Crevel, Ottenhoff, & van der Meer, 2002). We thus 
investigated whether the lack of ANXA1 affects the mycobacterial infection 
profile and TNF production by BMMΦ prepared from WT and ANXA1−/− 
mice. The results indicated comparable infection profiles in both ANXA1−/− 
and WT resting and activated BMMΦs with similar levels of TNF produced 
in the culture supernatants (Figure 3.6), suggesting that the transiently 
increased bacterial load seen in the lungs from ANXA1−/− mice is unlikely to 
have resulted from a direct impairment of infected macrophages to control 
intracellular mycobacterial multiplication. 
 
DCs are key immune cells linking innate and adaptive immunity. Upon 
interaction with a bacterial pathogen such as M. tuberculosis, DCs produce 
cytokines and mature to acquire migratory properties and ability to prime and 
activate naïve T cells in the draining LN (Wolf et al., 2008). M. tuberculosis-
infected ANXA1−/− BMDCs secreted higher levels of TNF, IL-6 and IL-10 
compared to the WT controls (Figure 3.7). This result is in apparent 
contradiction with the cytokine concentrations in the BALF from infected 
ANXA1−/− mice where lower levels of TNF were measured (Figure 3.4). The 
net concentration of cytokines measured in the BALF generally results from 
the interactions between several immune cell players and as such cytokine 
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production from a single cell population measured in vitro is unlikely to 
reflect the trend in vivo. Consistently, primary ANXA1−/− splenocyte cultures 
infected with M. tuberculosis produced significantly lower levels of TNF, IL-
6, IL-10 and IFNγ compared to WT splenocytes (Figure 3.8). These 
observations thus support that in vitro, infection of a total splenocyte 
preparation comprising of various immune cell types is better able to 
recapitulate the trend observed in vivo rather than an approach involving only 
a single cell population, underscoring the importance of interactions between 
various immune (and non-immune) cell populations that account for the 
overall host immune response.  
 
In addition to cytokine production profile, the maturation status of M. 
tuberculosis-infected ANXA1−/− BMDCs was investigated by flow cytometry 
analysis of several markers known to be up-regulated upon DC maturation: the 
co-stimulatory molecules CD80 and CD86 (Wallet, Sen, & Tisch, 2005), 
CD40 (Ma & Clark, 2009), MHCII (Shin et al., 2006) and CCR7 (Sallusto et 
al., 1998). Immature DCs express high levels of CCR5 that is down-regulated 
upon maturation (1998). We found that surface expression of CD80, CD86, 
CD40, MHCII and CCR7 were reduced in M. tuberculosis-infected ANXA1−/− 
BMDCs compared to M. tuberculosis-infected WT BMDCs (Figure 3.9). Our 
findings are similar to those reported by other groups using alternative 
stimulating antigens such as LPS (Huggins et al., 2009). It appears that the 
absence of ANXA1 impairs the maturation of DCs and ultimately affects their 
ability to prime naïve CD4+ T cells (Figure 3.10). This may be a result of the 
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decreased migratory activity of ANXA1−/− DCs in vivo that has previously 
been reported (2009). 
 
Taken together, our data show that the pleiotropic anti-inflammatory effects of 
ANXA1 indeed play an important role in restraining the immunopathology 
induced by M. tuberculosis infection. In several models of acute inflammation, 
numerous groups have linked much of the anti-inflammatory effects of 
ANXA1 to its powerful influence on neutrophil biology. Our work here 
supports a role of ANXA1 in the context of a chronic disease such as 
tuberculosis, where ANXA1 appears more critically involved in regulating the 
adaptive immune response via its impact on DC function, rather than on the 
innate anti-mycobacterial activity of immune cells.  
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3.4.  Future Work 
As mentioned earlier, it has been shown in vitro that M. tuberculosis may 
suppress host apoptotic mechanisms via ANXA1 as a means to promote its 
dissemination upon host cell necrosis (Gan et al., 2008), but this effect was 
not investigated in vivo. Thus, we planned to compare the extent of apoptosis 
versus necrosis in the lungs of ANXA1−/− and WT mice during infection with 
M. tuberculosis. To detect apoptotic cells, cells are typically stained with both 
Annexin V and propidium iodide (PI), and downstream flow cytometric 
analysis should be able to distinguish between viable, early apoptotic and late 
apoptotic/necrotic cells. In our case, because samples have to be fixed for 24h 
prior to flow cytometric acquisition outside of the BSL 3 laboratory, PI would 
be replaced with a fixable live/dead dye (Section 2.4.3). One of the problems 
we faced was poor resolution of the Annexin V stain. We think that one of the 
reasons for this may be the lack of calcium in the fixation buffer, which causes 
the detachment of Annexin V that had previously been bound to exposed 
phosphatidylserine in the presence of calcium in the staining buffer, especially 
after the mandatory long fixation period. This experiment remains to be 
optimised. 
 
As discussed in Section 1.5.2, neutrophil accumulation in the lungs appears to 
be associated with pathology and poor disease outcome. In view of the potent 
effects of ANXA1 on neutrophil biology (reviewed in Section 3.1), 
particularly in terms of inhibiting their migration, it would be interesting to 
monitor the recruitment of neutrophils to the lungs in ANXA1−/− mice in our 
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model of M. tuberculosis infection. This may be done by flow cytometric 
detection of Ly-6G+ cells. 
 
Finally, it would be worthwhile to evaluate the impact of glucocorticoid 
treatment on the pathogenesis of M. tuberculosis infection in both WT and 
ANXA1−/− mice in vivo, in terms of bacterial load, histopathology, cytokine 
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4.1.  Introduction 
4.1.1.  Heterogeneity of DCs  
DCs comprise a heterogeneous group of cells, which may be categorised into 
multiple distinct subsets based on their anatomical location, function and 
expression of cell surface markers. Much of our knowledge about human DC 
subsets is founded on studies of skin and blood samples; comparatively, our 
understanding of murine subsets is much more extensive. In fact, DCs were 
first discovered in the lymphoid organs of the mouse and their heterogeneity 
was first appreciated also using the mouse model (Schuler, Romani, & 
Steinman, 1985; Steinman & Cohn, 1974; Steinman & Cohn, 1973), which 
continues to provide invaluable insights into this field. The range of human 
DC subsets and their putative equivalents in the mouse are summarised in 
Figure 4.1 (Merad, Sathe, Helft, Miller, & Mortha, 2013; Shortman & Liu, 
2002). 
 
In the mouse, DCs are broadly classified into “steady-state” conventional DCs 
(cDCs), plasmacytoid DCs (pDCs) and monocyte-derived “inflammatory” 
DCs (Liu & Nussenzweig, 2010; Liu et al., 2009; Shortman & Naik, 2007). 
However, identification of monocyte-derived DC subsets that arise in the 
absence of inflammatory stimuli under steady-state conditions further 
complicates DC classification. cDCs are further divided into lymphoid-
resident DCs and migratory DCs, which are found in various peripheral 
organs, together with pDCs and monocyte-derived DCs (Figure 4.2). Here, we 
focused on the DC subsets found in the lungs and lung-draining mediastinal 
LN in the steady state and in the context of infection (Table 4.1).  




Figure 4.1. Human DC subsets. Summary of the phenotype and location of 
known human DC subsets and their putative equivalents in the mouse. 
Legend: cDC, conventional/classical DCs; pDCs, plasmacytoid DCs; LC, 
Langerhans cells; ND, not determined; PRRs, pattern-recognition receptors. 
Adapted from “The Dendritic Cell Lineage: Ontogeny and Function of 
Dendritic Cells and Their Subsets in the Steady State and the Inflamed 
Setting” by M. Merad et al., 2013, Annual Review in Immunology 31, pp. 563-








Figure 4.2. Mouse DC subsets. Mouse DCs are categorised as “steady-state” 
cDCs, pDCs and monocyte-derived “inflammatory” DCs. cDCs are further 
divided into lymphoid-resident DCs and migratory DCs, which are found in 
various peripheral organs, together with pDCs and monocyte-derived DCs. 
Adapted from “Complexity of dendritic cell subsets and their function in the 
host immune system” by R. Kushwah and J. Hu, 2011, Immunology 133:4, pp. 
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Table 4.1. Phenotypic markers to differentiate mouse DC subsets in the 













CD45 + + + + + 
CD11c +++ +++ ++ ++ + 
CLEC9A	  
(DNGR1) ++ − ++ − + 
CD8 + − − − subset 
CD103 subset − ++ − − 
CD11b − + − + − 
B220 − − − − + 
MHC	  class	  II ++ ++ ++ ++ + 
F4/80 − + − + − 
Ly6C − − − (+/−) ++ 
CD64 − − − (+/−) − 
CD172α	  (SIRPα) − ++ − ++ + 
CX3CR1 subset − − ++ − 
MAR-­‐1 − − − (+/−) ND 
Langerin subset − + − − 
CD205 ++ + ++ ND − 
CD209	   (DC-­‐
SIGN) − + − +/− ++ 
 
Note. Monocyte-derived dendritic cells that are recruited from the circulation 
to the lungs during inflammation or infection are phenotypically similar to 
CD103- CD11b+ cDCs, but may be differentiated from cDCs by their 
expression of MAR-1, CD64 and Ly6C. Adapted from “Division of labor 
between lung dendritic cells and macrophages in the defense against 
pulmonary infections” by M. Guilliams, B. N. Lambrecht and H. Hammad, 
2013, Mucosal Immunology 6(3), pp. 464-473, and, “The Dendritic Cell 
Lineage: Ontogeny and Function of Dendritic Cells and Their Subsets in the 
Steady State and the Inflamed Setting” by M. Merad et al., 2013, Annual 
Review in Immunology 31, pp. 563-604. Copyright 2013 by the Nature 
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4.1.2.  Lymphoid DC subsets  
Lymphoid organs such as the thymus, spleen and LN contain CD8+ CD4+ 
DCs, CD8− CD4− DCs and CD8− CD4+ DCs. CD8− CD4− and CD8− CD4+ 
DCs are collectively referred to as CD8− DCs, as they are more similar to each 
other than to CD8+ DCs, except for one functional aspect: CD8− CD4− DCs 
produce IL-12p70 under the appropriate stimuli, like their CD8+ counterparts, 
but CD4+ DC do not (Edwards et al., 2003). In the steady state, CD8+ DCs are 
found in the T cell areas, while CD8− DCs are restricted to the marginal zones 
and only migrate to the T cell areas when stimulated (Sathe & Shortman, 
2008; Steinman, Pack, & Inaba, 1997). 
 
CD8− CD4− DCs have been shown to be the predominant producer of IFNγ 
among lymphoid DC subsets (Hochrein et al., 2001). However, they are poor 
activators of CD8+ T cells in vitro and instead prime type 1 Treg cells, which 
secrete IL-10 and suppress the immune response (Zhang et al., 2005). It is 
suggested that in the steady state, CD8− CD4− DCs induce tolerance, but upon 
stimulation with toll-like receptor (TLR) 9 ligands, they assume an 
immunogenic phenotype and induce cytotoxic T cell responses (Zhang, 
Munegowda, Yuan, Wei, & Xiang, 2010). CD8− CD4+ DCs are unable to 
induce IFNγ production in T cells, and instead exert tolerogenic effects on Th1 
cells by IL-10 secretion (Legge et al., 2002). 
 
CD8+ DCs play a crucial role in immunity against viruses and intracellular 
pathogens, as they are the most potent producers of IFNα among lymphoid 
DCs, which increases the cytotoxicity of NK and T cells (Shortman & Heath, 
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2010). CD8+ DCs express CLEC9A, which acts as a receptor enabling the 
endocytosis of dead cells (Iyoda et al., 2002). The distinguishing characteristic 
of CD8+ DCs is their ability to cross-present exogenous antigens, soluble 
(Schnorrer et al., 2006) or endocytosed, via the MHC class I pathway (den 
Haan, Lehar, & Bevan, 2000). In conjunction with their secretion of high 
levels of IL-12p70 upon combined TLR and CD40 stimulation (Schulz et al., 
2000), CD8+ DCs are thus powerful inducers of effector CD8+ T cell 
responses to exogenous antigens. On the other hand, CD8− DCs, specialised 
for antigen presentation via MHC class II, induce CD4+ T cell responses 
(Dudziak et al., 2007). Recently, CD8+ DCs were shown to secrete IFNλ in 
response to polyinosinic:polycytidilic acid (poly IC) (Lauterbach et al., 2010). 
 
4.1.3.  Lung DC subsets  
The lung consists of three main DC subpopulations: CD103+ CD11b− cDCs in 
the intra-epithelial network, and CD103− CD11b+ cDCs and pDCs in the 
lamina propria of conducting airways (Lambrecht & Hammad, 2009). CD103+ 
DCs in the lung can migrate to the draining LN, produce IL-12 and are 
specialized in cross-presenting antigens to CD8+ T cells (del Rio, Rodriguez-
Barbosa, Kremmer, & Förster, 2007; Sung et al., 2006). Among resident 
pulmonary DCs, CD103+ DCs have been reported to be the major initiator of 
anti-viral CD8+ cytotoxic T cell responses (Beauchamp, Busick, & Alexander-
Miller, 2010; Pascual, Wang, Kochetkova, Callis, & Riccardi, 2008). In 
particular, CD103+ DCs have been critically implicated in protective 
immunity to influenza infection. Several groups have shown that CD103+ DCs 
efficiently transport influenza virus to the lymph node and present viral 
Chapter 4: The Role of CLEC9A+ Dendritic Cells in M. tuberculosis Infection 
 86 
antigen via MHC class I for cross-presentation to CD8+ T cells (Kandasamy et 
al., 2013; Moltedo et al., 2011; Ho et al., 2011) 
  
pDCs are present both in lymphoid and non-lymphoid organs and are 
primarily known for their rapid secretion of type I interferons during viral 
infection (Reizis, Bunin, Ghosh, Lewis, & Sisirak, 2011).  The role of 
pulmonary pDCs is controversial, with studies implicating them in both 
immunity (to viral infection) (Kushwah, Cao, & Hu, 2008) and tolerance (in 
asthma) (Lewkowich et al., 2008; de Heer et al., 2004). 
 
4.1.4.  DC subsets in mycobacterial infection 
Research on the involvement of DC subsets in mycobacterial infection is 
sparse, although a number of studies have suggested that various DC subsets 
may respond differently to mycobacterial challenge.  
 
It was shown that the adoptive transfer of CD8+ DCs isolated from BCG-
infected mice reduced the lung bacterial load of recipient mice that were 
subsequently challenged intra-nasal with BCG. In contrast, CD8− DC-
recipient mice showed no reduction in bacterial load and displayed enhanced 
inflammation. This was attributed to the fact that BCG-primed CD8− DCs 
produced higher levels of IL-10 and promoted immunosuppressive Th2 
responses compared to BCG-primed CD8+ DCs, which produced more of the 
protective Th1 cytokines, IL-12p70 and IFNγ (Gao et al., 2010). Additionally, 
elevated levels of intracellular IFNγ were detected in the CD8+ T cells of 
CD8+ DC-recipient mice compared to CD8− DC-recipient mice, raising the 
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possibility that CD8+ DCs were cross-presenting mycobacterial antigens to 
CD8+ T cells (2010), which is consistent with previous studies demonstrating 
that splenic CD8+ DCs cross-present exogenous antigens to CD8+ T cells, but 
CD8− do not (den Haan et al., 2000). Using IL-12p40-yellow fluorescent 
protein (YFP) reporter mice to evaluate IL-12p40 production in vivo after 
intravenous infection with BCG, Rothfuchs and colleagues showed that CD8+ 
DCs produced more IL-12p40 than CD8− DCs initially, but at three weeks 
post-infection, correlating with the onset of granuloma formation, CD8− DCs 
superseded CD8+ DCs in terms of IL-12p40 production. Furthermore, they 
discovered that mycobacterial infection suppressed IL-12p40 production of 
infected host cells (Rothfuchs et al., 2009). 
 
There are many unsolved questions regarding the role of lung CD103+ DCs in 
the context of mycobacterial infection. Interestingly, it has been observed that 
CD103+ DCs are more highly represented in the lungs of resistant C57BL/6 
and BALB/c mouse strains than susceptible DBA/2 mice during M. 
tuberculosis infection (Leepiyasakulchai, Ignatowicz, Pawlowski, Källenius, 
& Sköld, 2012). Pulmonary CD103+ CD11b− DCs are closely related to CD8+ 
DCs in origin (Edelson et al., 2010; Ginhoux et al., 2009) and it appears that 
many parallels can also be drawn for their function, most notably in terms of 
cross-presentation (Desch et al., 2011; Bedoui et al., 2009). Desch and 
colleagues showed that even though both CD11b+ and CD103+ DCs were able 
to ingest and traffic latex beads or soluble antigen, only CD103+ DCs could 
acquire and transport apoptotic cells to the draining LN and cross-present 
apoptotic cell-associated antigen to CD8+ T cells. It is likely that this shared 
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ability with CD8+ DCs is related to their expression of CLEC9A (Iyoda et al., 
2002). It is important to note that splenic lymphoid DCs are non-migratory, 
but are positioned to activate resident T cells present in the spleen. In contrast, 
it has been shown that initial T cell activation during M. tuberculosis infection 
depends on the mobilisation of bacteria or mycobacterial antigens from the 
lungs to the draining LN (Wolf et al., 2008). It is proposed that this role is 
assumed by the migratory DC subsets in the lungs.  
 
In an aerosol model of M. tuberculosis infection, it was shown that DCs are 
the predominant infected cell type in the lungs and LN, and CD11b+ DCs were 
infected at higher frequency than CD11b− DCs. However, infected CD11b+ 
DCs that had migrated from the lungs to the draining LN were less effective at 
stimulating IFNγ production by antigen specific CD4+ T cells compared to 
uninfected CD11b− DCs. They also demonstrated that M. tuberculosis can 
actively block MHC class II-restricted antigen presentation without any 
reduction in the surface expression of MHC class II (2007). This suggests that 
M. tuberculosis infection may curb direct antigen presentation in the LN, and 
that antigen is transferred from infected CD11b+ DCs from the lungs to 
CD11b− DCs in the LN. Such a mechanism has been reported before in a viral 
infection model in which antigen from skin-derived migratory DCs was 
transferred to lymph node resident DCs (Allan et al., 2006). These results 
imply that the effector functions of lung DC subsets may be modulated by 
mycobacteria to promote its persistence. 
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4.1.5. Mouse models for depletion of DCs in vivo  
The diphtheria toxin/diphtheria toxin receptor (DT/DTR) mouse model is 
currently the most efficient method to inducibly deplete cells in vivo. DCs can 
also been depleted in vivo using chloronate-loaded liposomes, but one major 
limitation of this approach is that all phagocytic cells will be targeted non-
specifically (Ward et al., 2011). For some DC subsets, such as pDC, depleting 
antibodies have been used with success in vivo, but for other subsets 
appropriate antibodies have yet to be identified (Swiecki, Wang, Gilfillan, & 
Colonna, 2013).  
 
DT is a highly toxic molecule but mouse cells are naturally 103 to 105 times 
more resistant to DT than human cells due to a three amino acid difference in 
the extracellular toxin-binding domain of the murine DTR. DTR-transgenic 
mice express the human DTR under the control of a tissue or cell-specific 
promoter. Thus, administration of DT, for example by intra-peritoneal 
injection, will selectively lead to the apoptotic death of the specific cell type 
expressing the receptor (Saito et al., 2001). In the absence of DT treatment, no 
immune abnormalities have been reported in any of the models expressing the 
human DTR. Currently available mouse models for depletion of DCs in vivo 
are summarised in Table 4.2.  
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Table 4.2. Currently available mouse models for depletion of DCs in vivo. 
 





cDCs and pDCs, but also certain 
macrophages, plasmablasts, 
activated T cells, NK cells, and 
Ly6Clo monocytes 
Tittel et al., 2012; Hildner et 
al., 2008; Jung et al., 2002 
zDC.DTR cDCs and probably certain 
activated monocytes 
Meredith et al., 2012 
Langerin.DTR LCs, Langerin+ dermal DCs, and 
certain lymphoid tissue DCs 
Bennett et al., 2005; 
Kissenpfennig et al., 2005 
BDCA2-DTR; 
SiglecH-DTR 
pDCs Takagi et al., 2011; Swiecki, 
Gilfillan, Vermi, Wang, & 
Colonna, 2010 
CLEC9A-DTR CD8+ DCs and likely, non-
lymphoid tissue CD103+ CD11b− 
DCs. Partial depletion of pDCs. 
Piva et al., 2012 
CD205-DTR CD8+ DCs, dermal DCs, and LCs Fukaya et al., 2012 
Constitutive deficiency 
CD11c-DTA cDCs, pDCs, LCs, and possibly 
certain macrophages, 
plasmablasts, activated T cells, 
NK cells, and Ly6Clo monocytes 
Ohnmacht et al., 2009; 
Birnberg et al., 2008 
Langerin-DTA LCs Kaplan, Jenison, Saeland, 
Shlomchik, & Shlomchik, 
2005 
Batf3−/− CD8+ DCs, non-lymphoid tissue 
CD103+ CD11b− DCs 
Hildner et al., 2008 
 
Note. LC, Langerhans cells. Adapted from “Advantages and limitations of 
mouse models to deplete dendritic cells” by J. van Blijswijk and B. U. 
Schraml, 2013, European Journal of Immunology 43(1), pp. 22-26. Copyright 
2013 by Wiley-VCH. Adapted with permission. 
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4.1.6.  Specific aims  
Here, we first report the use of the CLEC9A-DTR model to study the role of 
pulmonary CD103+ CD11b− DCs in M. tuberculosis infection. CLEC9A is a 
C-type lectin-like cell-surface molecule that is highly expressed by lymphoid 
CD8+ and non-lymphoid CD103+ cDC subsets, and to a lesser extent, pDCs. It 
is known to be tightly restricted to these DC subsets and is not detected on 
monocyte-derived inflammatory CD11cintCD11b+ DCs, macrophages, 
monocytes, T cells, NK cells nor B cells (Guilliams et al., 2013; Caminschi et 
al., 2008). So far, this model has been used to elucidate the role of CD8+ DCs 
in cerebral malaria (Piva et al., 2012).  
 
We aimed to determine the impact of pulmonary CD103+ CD11b− DCs in 
terms of controlling mycobacterial proliferation, as has been described for 
splenic CD8+ DCs by Gao and colleagues (Gao et al., 2010). We also aimed to 
investigate whether CD103+ CD11b− DCs affect the IL-12/IFNγ axis upon 
pulmonary mycobacterial infection, as reported for splenic CD8+ DCs by 
Rothfuchs and colleagues (Rothfuchs et al., 2009), while noting that the 
kinetics of cytokine production by lung DC subsets in response to 
mycobacterial infection may be very different from what has been reported for 
splenic DCs so far due to the initial delay in T cell activation after pulmonary 
infection. To address these aims, we monitored the bacterial load in both the 
lungs and draining LN of CLEC9A-depleted mice and also quantitatively and 
qualitatively characterised CD4+ and CD8+ T cell responses to M. tuberculosis 
infection.   
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4.2.  Results 
4.2.1.  Dendritic cell subsets found in the lungs and lung-draining LN in 
the steady state and during M. tuberculosis infection 
We first characterised the various dendritic cell subsets that are represented in 
the lungs and lung-draining mediastinal LN in the steady state, as well as 
during M. tuberculosis infection in our model. WT BALB/c mice were intra-
tracheally infected with M. tuberculosis H37Rv. At 7, 14 and 21 days post-
infection, whole lungs and mediastinal LN were prepared for flow cytometry. 
Samples were also prepared from uninfected mice (day 0; reflecting the 
“steady state”). In our analysis, we gated on live cells and singlets (doublet 
discrimination was based on FSC-H versus FSC-W), and the autofluoresence 
of AM (CD11c+) was used to distinguish them from non-autofluorescent DCs 
(plots not shown). We defined lung populations as follows: alveolar 
macrophages (AMs), F4/80+ CD11b+ MHCIIint; pDCs, SiglecH+ CD11cint; 
cDCs, B220− MHCII+ CD11c+. cDCs were further defined as CD103+ CD11b− 
B220− MHCII+ CD11c+ cDCs (“CD103+ cDCs”, our subset of interest) and 
CD103− CD11b+ B220− MHCII+ CD11c+ cDCs (“CD11b+ cDCs”) (Figure 
4.3A). LN pDCs, total cDCs, CD103+ cDCs and CD11b+ cDCs were defined. 
Additionally, lymphoid resident “CD8+ cDCs” could be distinguished from 
the other cDC subsets as the CD103− CD11b− population, and CD8 expression 
of this population was also confirmed (plot not shown) (Figure 4.3B). 
 
In the lungs, AMs initially outnumbered DCs during the steady state and at 
seven and 14 days post-infection. However, the AM population appeared to 
decrease as infection progressed, while the population of DCs increased, 
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particularly CD11b+ DCs. By 21 days post-infection, CD11b+ DCs became the 
most highly represented population in the lungs, while CD103+ DCs remained 
relatively rare (Figure 4.3C). In the LN, at seven and 14 days post-infection, 
equal numbers of CD11b+ and CD103+ DCs had accumulated, but by 21 days 
post-infection, CD11b+ DCs far exceeded all the other DC populations in the 
LN (Figure 4.3D). Our data indicates that CD11b+, not CD103+ DCs are the 
predominant DC population in the lungs and mediastinal LN during infection. 
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Figure 4.3. DC subsets found in the lungs and mediastinal LN in the 
steady state and during M. tuberculosis infection. WT BALB/c mice were 
intra-tracheally infected with 500 CFU of M. tuberculosis H37Rv.  Whole 
lungs and mediastinal LN were harvested from uninfected and infected 
animals at different time points post-infection, and single cell populations 
were prepared for flow cytometry analysis. (A) Representative dot plots 
showing the definition of AMs and DCs in the lungs. F4/80+ CD11b+ MHCIIint 
AMs, SiglecH+ CD11cint pDCs and B220− MHCII+ CD11c+ cDCs were 
identified. cDCs were further defined as CD103+ CD11b− B220− MHCII+ 
CD11c+ cDCs (“CD103+ cDCs”, our subset of interest) and CD103− CD11b+ 
B220− MHCII+ CD11c+ cDCs (“CD11b+ cDCs”). (B) Representative dot plots 
showing the definition of pDCs and cDC subsets in the LN. cDCs were further 
defined as CD103+ cDCs and CD11b+ cDCs, and additionally, lymphoid 
resident CD8+ CD11b− B220− MHCII+ CD11c+ cDCs (“CD8+ cDCs”). (C) 
Absolute numbers of AMs and DCs in the lungs at the indicated time points. 
(D) Absolute numbers of DCs in the LN, at the indicated time points. Results 
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4.2.2.  Intracellular distribution of M. tuberculosis in the lungs and 
mediastinal LN 
Next, we wanted to determine if M. tuberculosis was internalised by 
pulmonary CD103+ CD11b− DCs following intra-tracheal infection, and 
compared the distribution of M. tuberculosis bacteria amongst various DC 
subsets. We infected wild-type (WT) BALB/c mice with GFP-labelled M. 
tuberculosis H37Rv, and at seven, 14 and 21 days post-infection, whole-lung 
and LN homogenates were prepared for flow cytometry analysis. Lung and 
LN populations were defined as described in Section 4.2.1. (Figure 4.3). In the 
lung, CD103+ CD11b− DCs are a rare population; only approximately 1000 
cells are present in the whole lung in the steady state (uninfected). To ensure 
that we could consistently detect meaningful numbers (≥500) of infected 
(GFP+) cells within this population at as early as seven days post-infection, 
besides acquisition of the entire organ sample by flow cytometry, a higher 
inoculating dose (2000 CFU) was used in this case compared to the rest of the 
experiments described in this chapter, for which we adhered to the dose 
commonly used in low-dose aerosol models (500 CFU). A separate group of 
mice (n=2 mice per time point) was infected with the same dose of unlabelled 
H37Rv, to act as a negative control for gating on GFP+ cells. We quantified 
the number of CFU at 3h (day 0), 14 and 21 days post-infection and showed 
that there was no difference between the infection profiles of GFP-labelled 
and unlabelled bacteria in the lungs, indicating that expression of GFP in M. 
tuberculosis did not alter its ability to colonize murine lungs upon intra-
tracheal administration. The bacterial load in the lungs increased rapidly after 
exposure up to 21 days (Figure 4.4A and B), which corresponds to the 
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reported replicative phase of M. tuberculosis in low-dose aerosol mouse 
models (Section 1.8.1). Likewise, there was an increase in the total number of 
GFP+ cells in the lungs and the LN over the course of infection (Figure 4.4B). 
 
GFP+ cells could be detected within CD103+ CD11b− and CD103− CD11b+ 
DC subsets, as well as F4/80+ CD11b+ MHCIIint AMs. In contrast, the GFP 
signal was negligible in cells from control mice infected with unlabelled 
bacteria (negative control) (Figure 4.4C). In the lungs, at seven and 14 days 
post-infection, there were more GFP+ AMs than any of the other cell types 
analysed, and the GFP signal largely co-localised with the AMs. However, at 
21 days post-infection, there were more GFP+ DCs than AMs, and the GFP 
signal was mainly detected within the CD11b+ DC subset (Figure 4.4D). In the 
LN, significantly more GFP+ CD103+ DCs than GFP+ CD11b+ DCs had 
accumulated at seven and 14 days post-infection (Figure 4.4E). However, like 
in the lungs, by 21 days post-infection, there were more GFP+ CD11b+ DCs 
compared to the other DC subsets analysed, and majority of the GFP-labelled 
bacteria in the LN were found to be located within CD11b+ DCs. In relation to 
the non-lymphoid DC subsets assumed to have arrived from the lung, 
compared to non-lymphoid DC subsets, there was a consistently lower 
frequency of GFP+ CD8+ DCs, although by 21 days post-infection the number 
of GFP+ CD8+ DCs was comparable to GFP+ CD103+ DCs (Figure 4.4E).  
 
Altogether, our data show that pulmonary CD103+ CD11b− DCs are able to 
internalise M. tuberculosis. Initially in the lungs, M. tuberculosis infects AMs 
with the highest frequency, but subsequently more CD103− CD11b+ DCs get 
Chapter 4: The Role of CLEC9A+ Dendritic Cells in M. tuberculosis Infection 
 98 
infected. Interestingly, at early time points up to 14 days post-infection, there 
are more infected CD103+ CD11b− DCs than CD103− CD11b+ DCs in the LN, 
even though the latter subset is significantly more numerous in the lungs.  
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Figure 4.4. Intracellular distribution of M. tuberculosis in the lungs and 
mediastinal LN. Wild-type (WT) BALB/c mice were intra-tracheally infected 
with GFP-labelled or unlabelled M. tuberculosis H37Rv, and at seven, 14 and 
21 days post-infection, whole-lung homogenates were prepared for flow 
cytometry analysis. Lung and LN populations were defined as described in 
Section 4.2.1 (Figure 4.3). (A) Bacterial load in the lungs of mice infected 
with GFP-labelled and unlabelled bacteria at 3h (day 0), 14 and 21 days post-
infection. (B) Numbers of GFP+ cells in the lungs and the LN. (C) 
Representative plots (day 14) showing that GFP+ cells could be detected 
within CD103+ CD11b− and CD103− CD11b+ DC subsets, as well as F4/80+ 
CD11b+ MHCIIint AMs. (D) GFP+ total cDCs, CD103+ cDCs, CD11b+ cDCs 
and AMs in the lungs expressed in terms of absolute numbers or as a 
percentage of total GFP+ cells. (E) GFP+ total cDCs, CD103+ cDCs, CD11b+ 
cDCs and CD8+ cDCs in the LN expressed in terms of absolute numbers or as 
a percentage of total GFP+ cells. Results are expressed as the mean ± SEM 
(n=4 mice/group) and representative of two independent experiments.  
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4.2.3.  DT injection effectively depletes pulmonary CD103+ but not 
CD11b+ DCs 
In order to study the contribution of CD103+ CD11b− DCs during tuberculosis, 
the CLEC9A-DTR mouse model was employed where depletion of CLEC9A+ 
cells (mainly the CD103+ CD11b− DC subset) is achieved upon injection of 
DT. However, since the CLEC9A-DTR model had not been used to study M. 
tuberculosis infection before, we had to confirm that intra-peritoneal injection 
of DT at the frequency and concentration (as low as 10ng/g body weight is 
sufficient) optimised to deplete the targeted subset would not interfere with the 
profile of infection and the immune response. WT BALB/c mice were thus 
intra-tracheally infected with 500 CFU of M. tuberculosis H37Rv, and DT 
(10ng/g body weight) was injected one day prior to infection and subsequently 
every four to five days throughout the course of infection. Control mice were 
injected with diluent only. The infection profile was monitored up to 56 days 
(eight weeks) post-infection by quantifying the bacterial load in the lungs. 
CFU counts between mice injected with DT and mice injected with diluent 
only were similar. In uninfected mice, histology indicated no detectable 
inflammation in the lungs and spleen of mice after eight weeks of regular DT 
injection (Figure 4.5A). 
 
We next checked the effectiveness of the DT treatment in depleting our 
targeted subset. CLEC9A-DTR mice were intra-tracheally infected with 500 
CFU of M. tuberculosis H37Rv. As described previously, DT was injected one 
day prior to infection and subsequently every four to five days throughout the 
course of infection in order to maintain depletion of the targeted subset. Our 
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results confirmed that by one day (20 to 24 hours) after the first DT injection, 
approximately 99% of pulmonary CD103+ CD11b− DCs were depleted, thus 
ensuring the absence of this subset from the time of infection. Regular 
injection effectively suppressed the presence of pulmonary CD103+ CD11b− 
DCs for up to three weeks, but had no effect on CD103− CD11b+ DCs (Figure 
4.5B). From three weeks after the first DT treatment onwards, depletion of 
CD103+ CD11b− DCs was not as effective or consistent, with recovery of the 
CD103+ CD11b− DC subset in “depleted” mice reaching approximately 60% 
of control levels or higher (data not shown). We hypothesised that the gradual 
revival of the targeted subset could be due to the production of neutralising 
antibodies against DT, thus limiting this model temporally. Nevertheless, this 
model appears to be useful for elucidating early immune responses to 
tuberculosis; in particular, testing our hypothesis that the CD103+ CD11b− DC 
subset is important in the initiation of the adaptive immunity against M. 
tuberculosis infection, which in mice manifests at around three weeks post-
infection. 
 
It is worth noting that it has been reported that DT injection in CLEC9A-DTR 
mice results in the partial loss of pDCs, which express low levels of CLEC9A 
(Piva et al., 2012). A role for pDCs in M. tuberculosis infection has not yet 
been established and is not the focus of our work; however, we wished to 
appraise the relative contribution of pDCs in the context of understanding if 
partial loss of this population would critically affect the interpretation of our 
experimental results. To address this aspect, SiglecH-DTR mice were intra-
tracheally infected with M. tuberculosis H37Rv. DT was injected one day 
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prior to infection and subsequently every four to five days to deplete pDCs, as 
described by Piva and colleagues. Depletion of pDCs did not have any effect 
on the bacterial load in the lungs and spleens of infected mice up to 21 days 
post-infection, suggesting that the contribution of pDCs in the control of M. 
tuberculosis infection is negligible, at least during our experimental time 
frame (Figure 4.5C). 
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Figure 4.5. Effects of DT injection. (A) WT BALB/c mice were intra-
tracheally infected with M. tuberculosis H37Rv, and DT (10ng/g body weight) 
was injected one day prior to infection and subsequently every four to five 
days throughout the course of infection. Control mice were injected with 
diluent only. The infection profile was monitored up to 56 days (eight weeks) 
post-infection by quantifying the bacterial load in terms of CFU after culture 
of whole organ homogenates on 7H11 agar. Lung and spleen CFU counts of 
mice injected with DT and mice injected with diluent only are shown, as well 
as representative H&E-stained histological sections prepared from the lungs 
and spleens of mice after eight weeks of regular DT injection. (B) CLEC9A-
DTR mice were intra-tracheally infected with M. tuberculosis H37Rv. DT was 
administered as described in (A). Numbers of CD103+ and CD11b+ DCs with 
and without DT treatment are shown. (C) SiglecH-DTR mice were intra-
tracheally infected with M. tuberculosis H37Rv. DT was administered as 
described in (A). Lung and spleen CFU counts in mice depleted of pDCs and 
controls are shown. Results are expressed as the mean ± SEM (n=4 
mice/group). (A) and (C) are representative of two independent experiments; 








































































































































































































Chapter 4: The Role of CLEC9A+ Dendritic Cells in M. tuberculosis Infection 
 105 
4.2.4.  Depletion of pulmonary CD103+ CD11b− DC subset results in a 
higher bacterial burden in the lungs 
To assess the ability of mice depleted of pulmonary CD103+ CD11b− DCs to 
control M. tuberculosis infection, CLEC9A-DTR mice were intra-tracheally 
infected with 500 CFU of M. tuberculosis H37Rv and the bacterial load in the 
lungs, lung-draining LN and spleen were quantified from 3h after infection 
(day 0) to 21 days (in the lungs and LN) or 28 days (in the spleen). Infected 
mice were divided into two groups; control mice did not receive DT treatment 
while “depleted” mice were subject to DT injection resulting in the ablation of 
CLEC9A+ DCs, namely migratory lung CD103+ CD11b− DCs and lymphoid-
resident, non-migratory CD8+ CD11b− DCs in the spleen and LN.  
 
Our results show that CLEC9A+ DC-depleted mice displayed a higher 
bacterial load in the lungs than controls from seven to 21 days post-infection 
(Figure 4.6A). We were able to detect bacteria in the LN from seven days 
post-infection, in control mice that averaged about 840 CFU and in the 
depleted mice about 200 CFU. We observed a higher bacterial load in the LN 
of control mice from seven to 14 days post-infection, but by 21 days post-
infection, more bacteria were found in the LN of CLEC9A+ DC-depleted 
mice, mirroring the trend observed in the lungs (Figure 4.6B).  
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Figure 4.6. Bacterial load in the lungs and mediastinal LN in control vs. 
CLEC9A+ DC-depleted mice. CLEC9A-DTR mice were intra-tracheally 
infected with M. tuberculosis H37Rv. One group was subjected to DT 
injection one day prior to infection and subsequently every four to five days 
throughout the course of infection in order to maintain depletion of the 
targeted subset. At 3h (day 0), seven, 14, 21 and 28 days post-infection, lungs 
and mediastinal LN were homogenised and appropriate dilutions of the whole 
organ homogenates were cultured on 7H11 agar. CFU were quantified after 
incubation for 16 to 21 days. Bacterial load in the (A) lungs and (B) LN of 
CLEC9A+ DC-depleted mice and controls are shown. Results are expressed as 
the mean ± SEM (n=4 mice/group). The experiment was repeated at least 
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4.2.5.  Depletion of pulmonary CD103+ CD11b− DC subset results in 
reduced expression of key Th1 cytokines in the lungs 
To understand the possible mechanisms underlying the differences in bacterial 
burden observed between CLEC9A+ DC-depleted mice and controls, local 
cytokine concentrations in the lung were determined by assaying the BALF. 
Compared to controls, the level of IFNγ was significantly reduced in 
CLEC9A+ DC-depleted mice at 21 days post-infection, and these mice also 
expressed lower levels of TNF at 14 and 21 days post-infection. There was no 




Figure 4.7. Local cytokine responses in the lung. CLEC9A-DTR mice were 
intra-tracheally infected with M. tuberculosis H37Rv. One group was treated 
with DT to sustain depletion of the targeted subset. BALF was collected from 
naïve (day 0) and infected mice at the indicated time points, and cytokine 
concentrations were measured by ELISA. Results are expressed as the mean ± 
SEM (n=4 to n=5 mice/group). The experiment was repeated twice; a 
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4.2.6. Depletion of pulmonary CD103+ CD11b− DC subset is associated 
with impairment of T cell activation and effector functions 
The significantly reduced IFNγ concentration in the lungs of CLEC9A+ DC-
depleted mice prompted us to examine the activation status of T cells in the 
lungs, as well as in the LN, as activated T cells are known to be major 
producers of this cytokine in response to M. tuberculosis infection (Cooper & 
Khader, 2008). In the LN, CLEC9A+ DC-depleted mice showed reduced total 
and activated CD8+ and CD4+ T cell numbers across all the time points 
monitored (Figure 4.8B and C). In the lungs, CLEC9A+ DC-depleted mice 
also had consistently less total and activated CD8+ T cells (Figure 4.8D). The 
impact of depleting CLEC9A+ DCs on CD4+ T cell activation was less clear. 
At 14 days post-infection, CLEC9A+ DC-depleted mice showed a slight 
reduction in total and activated CD4+ T cells numbers, keeping with the trend 
observed for CD8+ T cells (Figure 8E). However, at 21 days post-infection, 
there was an appreciably greater accumulation of total and activated CD4+ T 
cells in the lungs of CLEC9A+ DC-depleted mice compared to controls 
(Figure 4.8E). 
 
Production of IFNγ is an important effector function of both CD4+ and CD8+ 
T cells (Cooper 2009b). We were unable to detect intracellular IFNγ in the 
activated T cell populations shown in Figure 4.8, and we postulated that this 
could be due to the fact that IFNγ is rapidly secreted and these cells do not 
accumulate the cytokine intracellularly. Hence, at 21 days post-infection, 
which coincides with the onset of acquired cellular immunity and when there 
is substantial T cell infiltrate in the lungs, we prepared single cell suspensions 
Chapter 4: The Role of CLEC9A+ Dendritic Cells in M. tuberculosis Infection 
 109 
of whole lungs and LNs for re-stimulation in vitro, using either tuberculin 
purified protein derivative (PPD) or a mitogenic cocktail (PMAI) containing 
phorbol 12-myristate 13-acetate (PMA) and ionomycin. BrefeldinA was added 
to cultures when appropriate to inhibit the secretion process, and intracellular 
IFNγ produced and accumulated inside CD4+ or CD8+ T cells was detected by 
flow cytometry.  
 
As PPD is a mixture of mycobacterial proteins, IFNγ production measured in 
response to PPD treatment is reflective of the magnitude of the mycobacterial 
antigen-specific T cell response. We assume that under the experimental 
conditions, T cells that rapidly produce IFNγ after short-term in vitro 
stimulation with PPD have previously been presented with M. tuberculosis 
antigen in vivo. PMA on the other hand is a small organic compound that 
diffuses through the cell membrane where it directly activates cytoplasmic 
PKC without surface receptor stimulation. Previously activated T cells will 
rapidly produce IFNγ production while in the case of naïve T cells, 
proliferation will precede cytokine production hence within the same time 
frame, the levels of cytokine measured are expected to be lower (Brenchley et 
al., 2002).  
 
Both PPD and PMAI treatment consistently induced a reduced proportion of 
IFNγ-producing CD8+ T cells in the LN (Figure 4.9A) and lungs (Figure 4.9B) 
of CLEC9A+ DC-depleted mice compared to controls. There was no 
detectable difference in the proportion of IFNγ-producing CD4+ T cells after 
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PPD treatment in the LN and lungs of mice from both groups, although PMAI 
treatment yielded similar differences as the CD8+ T cells.  
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Figure 4.8. T cell activation in the lungs and mediastinal LN. CLEC9A-
DTR mice were intra-tracheally infected with M. tuberculosis H37Rv. One 
group was treated with DT to sustain depletion of the targeted subset. At the 
indicated time points post-infection, whole lung and mediastinal LN were 
processed for flow cytometry. (A) T cells were identified as CD4+ or CD8+, 
and the activation status of each subset was further analysed. Activated T cells 
were identified as CD69+ and also CD44+ CD62L−. Representative plots are 
shown. (B) Activation of LN CD8+ and (C) CD4+ T cells. (D) Activation of 
CD8+ and (E) CD4+ T cells in the lungs. Results are expressed as the mean ± 
SEM (n=4 mice/group). The experiment was repeated twice; a representative 
experiment is shown. *p<0.05, **p<0.01. 
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Figure 4.9. Re-stimulation of T cells in vitro. CLEC9A-DTR mice were 
intra-tracheally infected with M. tuberculosis H37Rv. One group was treated 
with DT to sustain depletion of the targeted subset. At 21 days post-infection, 
whole lungs and mediastinal LN were re-stimulated in vitro using either PPD 
or a mitogenic cocktail (PMAI) containing PMA and ionomycin. (A) 
Intracellular IFNγ produced by CD4+ or CD8+ T cells was detected by flow 
cytometry. Representative plots shown are based on LN samples. (B) 
Percentage of CD4+ or CD8+ T cells that were IFNγ+ following re-stimulation 
of lung cells. (C) Percentage of CD4+ or CD8+ T cells that were IFNγ+ 
following re-stimulation of LN cells.  Results are expressed as the mean ± 
SEM (n=4 mice/group). The experiment was repeated twice; a representative 
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4.3.  Discussion 
4.3.1.  DCs increase in importance as a bacteria reservoir relative to AMs 
as M. tuberculosis infection progresses 
The role of macrophages as the primary host for M. tuberculosis has been 
recognized for decades, but it is unlikely that pulmonary macrophages alone 
have the capacity to initiate cellular immune responses. A previous study had 
indeed compared the migratory potential of DCs and AM and showed that 
even though AMs acquired the majority of intra-nasally delivered latex 
particles, transport of the particles to the draining LN for antigen presentation 
and activation of naïve T cells depended exclusively on DCs (Jakubzick, 
Tacke, Llodra, van Rooijen, & Randolph, 2006). DCs in human (Tailleux et 
al., 2003a) and mouse (Humphreys et al., 2006) tissues were found to contain 
mycobacteria. Wolf and colleagues were the first to use GFP-labelled M. 
tuberculosis to study its distribution amongst phagocytes, discovering that in 
fact myeloid DCs are the major cell population infected with M. tuberculosis 
in the lungs and lung-draining LN (Wolf et al., 2007). In their study, they 
relied only on the relative expression of CD11b and CD11c to distinguish 
between AM, myeloid DCs, and various myeloid DC “subsets”. We took this 
one step further and monitored the various DC populations and AMs in the 
lungs and LN during M. tuberculosis infection, using a range of DC subset-
specific phenotypic markers (Figure 4.3A and B). Our observation that the 
AM population decreases as infection progresses while DCs increase in the 
lungs (Figure 4.3C) corroborates with the findings of Wolf and colleagues. We 
confirm that M. tuberculosis indeed infects various lung DC subsets, 
including, specifically, pulmonary CD103+ CD11b− DCs (Figure 4.4C). We 
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show that while AMs are an important early niche for bacterial replication, at 
later stage during the infection, more bacteria in the lungs are located within 
the DC compartment, particularly, in CD11b+ DCs (Figure 4.4D). 
 
4.3.2.  CD103+ DCs play a crucial role in the rapid mobilisation of 
bacteria to the LN soon after infection with M. tuberculosis 
In uninfected mice, the LN originally contains only a small population of 
lymphoid-resident DCs, which are either CD8+ CD11b− or CD8− CD11b+. 
Pulmonary CD103+ CD11b− and CD103− CD11b+ DCs are not naturally 
present in the LN in steady state conditions. Here, CD8− CD11b+ and CD103− 
CD11b+ are collectively referred to as CD11b+ DCs. These cells are 
indistinguishable in vivo in terms of function or phenotype, and the CD11b+ 
subset is generally known to differentiate from circulating monocytes 
(Murine: Ly-6C+ GR-1+ CCR2+ CX3CR1lo L-selectin+; Human: CD14hi 
CD16−) into CD11b+ CD11c+ DCs within the local inflammatory environment 
(León, López-Bravo, & Ardavín, 2005), in this case, the lungs. CD11b+ DCs 
are known to be highly migratory, expressing several chemokine receptors 
including CCR2, CCR5 and CCR6 (León & Ardavín, 2008). CD103+ DCs 
have also been shown to migrate from various peripheral organs to the 
draining LN (Waithman et al., 2013); Desch et al., 2011; Scott, Aumeunier, & 
Mowat, 2011). Hence, it is fair to assume that CD103+ and CD11b+ DCs 
found in the lung-draining LN after pulmonary infection have migrated from 
the lungs.  
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Significantly, soon after infection (up to 14 days), more infected CD103+ DCs 
accumulate in the LN than CD11b+ DCs initially, despite lower numbers in the 
lungs (Figure 4.4E). Our data suggest that initially, CD103+ DCs are the more 
efficient migratory subset compared to CD11b+ DCs and play a crucial role in 
the rapid mobilisation of bacteria to the LN. As infection progresses, CD11b+ 
DCs eventually overtake CD103+ DCs in this function, due to sheer numbers 
of them being recruited to the lungs as part of the inflammatory response.  
 
It is worth noting that GFP− DCs were also found to accumulate in the LN, as 
this highlights a limitation of our experiments in Figures 4.3 and 4.4, in which 
the cellular localisation of M. tuberculosis was detected by GFP fluorescence. 
Firstly, proper folding of GFP is required for fluorescence and it is likely that 
this is lost during antigen processing (Ghimire, Benson, Garside, & Brewer, 
2012); thus, it is still possible that GFP− CD103+ or CD11b+ DCs arriving 
from the lung were previously infected and may present mycobacterial 
antigens to T cells in the LN. Secondly, DCs can also acquire antigen by 
means other than direct infection, such as via phagocytosis of bacterial 
products or apoptotic vesicles bearing mycobacterial antigens (Girvan, 
Aldwell, Buchan, Faulkner, & Baird, 2003; Schaible et al., 2003). Lastly, DCs 
migrating to the LN may not necessarily have to bear antigen or intact bacteria 
(GFP+); the inflammatory milieu in the lungs may be sufficient to induce DC 
maturation and up-regulation of surface chemokine receptors making them 
competent for migration and subsequent activation of naïve T cells.  
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4.3.3.  CD103+ DCs contribute to the control of bacterial burden during 
M. tuberculosis infection  
We showed that the depletion of CLEC9A+ DCs resulted in a higher bacterial 
load in the lungs of mice infected with M. tuberculosis (Figure 4.6A), 
suggesting that CLEC9A+ DCs contribute to the control of bacterial load 
during the replicative phase of the bacteria, which in the mouse model is up to 
three weeks post-infection. Depletion of CLEC9A+ DCs resulted in a lower 
bacterial load in the LN from seven to 14 days post-infection (Figure 4.6B). 
This observation seems to correlate with our finding that CD103+ DC 
transport mycobacteria effectively to the draining LN during the early stage of 
infection (see section above). However, at 21 days post-infection, more 
bacteria were recovered in the LN of CLEC9A+ DC-depleted mice, reflecting 
the higher bacterial load and overwhelming presence of migratory CD11b+ 
DCs in the lungs. 
 
It is important to consider that the route of exposure critically affects the DC 
subsets infected or activated. Intravenous inoculation will deposit most of the 
bacteria in the spleen, where lymphoid-restricted DC subsets are present, 
which was the route of exposure chosen by the groups attempting to 
understand the role of CD8+ DCs in mycobacterial infection as reviewed in 
Section 4.1.4 (Gao et al., 2010; Rothfuchs et al., 2009). Aerosol, intratracheal 
or intranasal infection will instill the bacteria in the lungs, where they will first 
encounter pulmonary DC subsets. At least in the lung and LN from exposure 
via the intra-tracheal route until 14 days later, it may be justified to assume 
that the contribution of lymphoid CD8+ DCs present in the LN is minor at best 
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in relation to that of the pulmonary subsets, as the initial delay in the arrival of 
bacteria or antigen from the lung to the LN has been widely acknowledged 
and documented to be detectable 14 days post-infection (Wolf et al., 2008).  
 
Thus, our results further support a role for CD103+ DCs in the transport of 
(viable) bacteria from the lungs to the LN early after infection, and also our 
hypothesis that the proliferation of bacteria in the lungs and local 
inflammatory response results in the increased presence and infection of 
CD11b+ DCs, which, by sheer numbers, subsequently become the 
predominant vehicle for shuttling bacteria to the LN. We acknowledged earlier 
that pDCs may also be partially depleted in our CLEC9A-DTR model, but we 
showed that the specific depletion of pDCs (Figure 4.5C) did not affect 
bacterial load, therefore the effects observed in Figure 4.6 are likely to be 
attributed to the loss of CD103+ DCs.  
 
4.3.4.  CD103+ DCs play an important role in the initiation of T cell 
responses during M. tuberculosis infection 
Our data clearly demonstrated the importance of CD103+ DCs in CD8+ T cell 
activation (Figure 4.8B and D). This is consistent with previous reports of 
cross-presentation capabilities that appear to be unique to this subset (Desch et 
al., 2011; Bedoui et al., 2009), which may be related to their expression of 
CLEC9A (Iyoda et al., 2002). It was shown that CD103+ DCs but not CD11b+ 
DCs could acquire and transport apoptotic cells to the draining LN and cross-
present apoptotic cell-associated antigen to CD8+ T cells (Desch et al., 2011).  
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Tian and colleagues have previously shown that depletion of CD11c+ cells in 
CD11c-DTR transgenic mice before intravenous injection of M. tuberculosis 
delays the development of CD4+ T cell responses and results in a higher 
bacterial burden (Tian et al., 2005), suggesting an important role for DCs in 
the induction of CD4+ T cell responses. However, apart from the fact that the 
concurrent depletion of immune cells other than DCs and the induction of 
neutrophilia and monocytosis in CD11c-depletion models upon DT treatment 
may confound the interpretation of results (van Blijswijk & Schraml, 2013), 
the route of inoculation may not accurately recapitulate pulmonary infection 
and the early exposure of pulmonary DCs. Here, we establish the relative 
importance of CD103+ DCs in relation to other DC subsets in the activation of 
CD4+ T cells (Figure 4.8C and E). In the LN, depletion of CD103+ DCs 
resulted in a decrease in total and activated CD4+ T cells across all time points 
monitored. This was also the case in the lungs up to 14 days post-infection; 
however, at 21 days post-infection, the reverse was observed. Detection of 
IFNγ-producing T cells after in vitro re-stimulation with mycobacterial 
antigens (PPD) of lung and LN cells harvested from CLEC9A+ DC-depleted 
mice at 21 days post-infection corroborate closely with our quantification of 
activated T cells in those organs in vivo (Figure 4.9).  Our data indicate that 
the CD103+ DC subset is critical to CD8+ T cell activation, and also 
contributes to the early activation of CD4+ T cells. We hypothesize that by 21 
days post-infection, as infected CD11b+ DCs vastly outnumber CD103+ DCs 
in the lungs (lymphoid-restricted CD8+ DCs are not present), at this later stage 
naïve T cells recruited to the inflammatory milieu may be mainly activated by 
antigen-presenting CD11b+ DCs. As a result, the absence of CD103+ DCs not 
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only does not appear to impair CD4+ T cell activation, the increased number 
of activated CD4+ T cells observed is likely in response to the increased 
bacterial burden, which was an indirect outcome of the impairment of early 
CD8+ and CD4+ T cell responses. 
 
The predominant protective effector functions of activated T cells in M. 
tuberculosis are mediated by their secretion of the Th1 cytokines IFNγ and 
TNF. Activated T cells are important sources of IFNγ that is essential to 
control bacterial growth (Tully et al., 2005; Jung et al., 2005; Fenhalls et al., 
2002; Chackerian et al., 2001). Macrophages are a major early source of TNF 
in the lungs, which is subsequently also produced by recruited Th1 cells 
(Algood et al., 2005). We showed that the level of IFNγ was significantly 
reduced in the lungs of CLEC9A+ DC-depleted mice at 21 days post-infection, 
coinciding with the expected arrival of IFNγ-secreting T cells; in addition, 
TNF concentrations were also lower at 14 and 21 days post-infection (Figure 
4.7). Taken together, our data provide a mechanism to account for the higher 
bacterial load in the lungs observed in CLEC9A+ DC-depleted mice.  
 
4.3.5.  Proposing a role for the lung CD103+ DC subset in the early 
transport of bacteria to the LN after pulmonary exposure to M. 
tuberculosis, a critical determinant of host resistance 
Although TB is a chronic disease, the early immunological events that follow 
M. tuberculosis infection can have a profound impact on the pathogenesis and 
outcome of disease. It has been shown that early production of IFNγ by CD4+ 
or CD8+ T cells affects the susceptibility of mice infected with M. tuberculosis 
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(Caruso et al., 1999). Early bacterial dissemination in resistant mice correlates 
with early recruitment of T cells to the lungs (Mischenko et al., 2004), the 
initiation of antigen-specific T cell responses and granuloma formation 
(Chackerian, Alt, Perera, Dascher, & Behar, 2002). A key aspect of the 
adaptive immune response is the kinetics of its expression. Studies in both 
mice and non-human primates suggest that unlike many acute bacterial 
infections, the onset of the adaptive immune response is delayed after 
exposure to M. tuberculosis, not occurring until 14 to 21 days (Wolf et al., 
2008; Lin et al., 2006; Chackerian et al., 2002), allowing the bacteria to first 
establish itself in numbers. T cell priming is a necessary step in the induction 
of a protective adaptive immune response to TB, and in a seminal report by 
Wolf and colleagues, it was shown that this initially occurs in the LN, and not 
in the lungs, despite the presence of 100-fold more bacteria (Wolf et al., 
2008). Delayed mycobacterial dissemination to the LN reported in plt mice, 
which lack expression of the CCR7 ligands CCL19 and CCL21ser, was 
associated with delayed T cell activation (2007).  
 
Based on our findings, we propose a crucial role for the lung CD103+ DC 
subset in the early transport of mycobacteria to the LN after pulmonary 
exposure to M. tuberculosis and the activation of both CD8+ and CD4+ T cells. 
As infection progresses, CD11b+ DCs gradually increase in importance as 
bacterial reservoirs largely due to their increased presence in the lungs and 
phagocytic ability. CD11b+ DCs also transport bacteria to the LN and activate 
T cells, but in the early stages of infection, even though they still outnumber 
CD103+ DCs in the lungs (but to a lesser extent than in later stages), they 
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appear to be less efficient in performing this function (Figure 4.10). It could be 
a result of differential expression of chemokine receptors or other surface 
receptors, affecting their migratory potential, or rendering them less capable of 
acquiring mycobacteria. This aspect remains unexplored, and it would be 
interesting to further characterise the functional differences between the 
different DC subsets in the context of M. tuberculosis infection. 
  
At this juncture, we would like to point out that the population we have 
identified in this Thesis as “CD11b+ DCs” is in fact heterogeneous. In the 
lungs, it includes steady state lung cDCs as well as monocyte-derived 
“inflammatory DCs” (infDCs). In the LN, it includes steady state resident LN 
cDCs, migratory lung cDCs as well as infDCs (Figure 4.10). We hypothesise 
that the expansion of the CD11b+ DC population in the lungs during M. 
tuberculosis infection is predominantly driven by the recruitment of 
monocytes that give rise to infDCs, and relatively less dependent on the 
differentiation of CD11b+ cDCs from cDC precursors (Shortman & Naik, 
2007). 
 
While there is a great deal of overlap between lymphoid-resident CD11b+ 
cDCs and migratory CD11b+ cDCs in the periphery, there are certain surface 
markers expressed on infDCs but not steady state DCs (Segura & Amigorena, 
2013). “CD11b+ DCs” are not the focus of our study but given our findings 
thus far, it would be interesting to differentiate inflammatory CD11b+ DCs 
from steady state CD11b+ DCs in future work (Section 4.4).   
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A phenomenon that puzzled us was the low proportion of CD103+ DCs in 
relation to CD11b+ DCs that we observed in the lungs. The distinction of these 
two subsets in the context of mycobacterial infection has so far only been 
made by two groups. The data generated by Wolf and colleagues reflected a 
higher CD11b− to CD11b+ DC ratio during M. tuberculosis infection (Wolf et 
al., 2007) than we found in our model; on the other hand, Humphreys and 
colleagues, like us, noted that (BCG-) infected DCs were predominantly 
CD11b+ (Humphreys et al., 2006). Only recently was it discovered that upon 
M. tuberculosis infection, C57BL/6 mice, the strain used by Wolf and 
colleagues, exhibit a higher frequency of lung CD103+ DCs than BALB/c 
mice, the background of our experimental model and that of Humphreys and 
colleagues (Sérgio, Bertolini, Gembre, de Queiroz Prado, & Bonato, 2014). In 
the same study, it was shown that C57BL/6 mice generated stronger IFNγ 
responses than BALB/c mice, underscoring the influence of host genetic and 
immune factors in M. tuberculosis infection. Although this information 
suggests that perhaps it may be more suitable to use a mouse model with a 
C57BL/6 rather than BALB/c background in our attempt to elucidate the role 
of CD103+ DCs, the fact that our model produced appreciable differences in 
terms of disease burden and immune responses upon depletion of the 
numerically “minor” CD103+ DC subset only emphasises the relative 
importance of this subset in protective immunity to M. tuberculosis infection. 
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Figure is continued on the next page 
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Figure is continued on the next page 
  
Chapter 4: The Role of CLEC9A+ Dendritic Cells in M. tuberculosis Infection 
 125 
 
Figure caption is on the next page 
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Figure 4.10. Schematic illustrating the proposed role of the pulmonary 
CD103+ DC subset in relation to other DC subsets. (A) Based on the 
current model of DC ontology, which has been extensively reviewed by 
Shortman and Naik (Shortman & Naik, 2007), in the bone marrow, CMPs give 
rise to MDPs that differentiate into CDPs and monocytes. Monocytes and the 
progeny of CDPs, i.e. pDCs (not shown) and pre-cDCs enter the blood 
circulation, through which they reach the LN and lungs. There, pre-cDCs 
undergo a final differentiation stage into CD8+ and CD11b+ DCs in the LN 
and CD103+ and CD11b+ DCs in the lungs. (B) During the early stages of 
pulmonary infection, monocytes are recruited to the lungs (reviewed in 
Sections 1.5 and 1.6) and give rise to infDCs. We propose that at this stage, 
the migratory lung CD103+ DC subset plays a crucial role in the transport of 
mycobacteria to the LN and the activation of both CD8+ and CD4+ T cells. (C) 
As infection progresses, CD11b+ DCs gradually increase in importance as 
bacterial reservoirs largely due to their increased presence in the lungs. We 
hypothesise that the expansion of the CD11b+ DC population in the lungs 
during M. tuberculosis infection is predominantly driven by the recruitment of 
monocytes that give rise to infDCs. CD11b+ DCs also transport bacteria to the 
LN and activate T cells.  Legend: Black arrows, movement/differentiation; 
red arrows, effector functions; CMP, common myeloid progenitor; MDP, 
monocyte/DC progenitor; CDP, common DC progenitor; Mono, monocyte; 
pre-cDC, pre-conventional DC; AM, alveolar macrophage; infDC, 
inflammatory DC; Act-TC, activated T cell. 
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4.4.  Future Work 
We mentioned earlier in the Discussion that it would be interesting to 
differentiate inflammatory CD11b+ DCs (infDC) from steady state CD11b+ 
DCs. InfDCs have been implicated in various conditions of pathogen-induced 
inflammation, such as parasitic, viral and bacterial infections (Greter et al., 
2012; Ballesteros-Tato, León, Lund, & Randall, 2010; Zhan et al., 2010), 
including pulmonary M. tuberculosis infection (Mayer-Barber et al., 2011). 
Table 4.3 summarises the phenotypic identification of infDCs and highlights 
the exceptional difficulty of differentiating them from macrophages. It seems 
that the best strategy to gate on infDCs in both peripheral and lymphoid 
tissues involves the co-analysis of CD64 and FcɛRI (Plantinga et al., 2013). 
We have yet to optimise the use of commercially available FcɛRI antibodies 
for this purpose. Ideally, we would include the analysis of infDCs as a 
separate subset from CD11b+ cDCs in our experiments with WT mice infected 
with GFP-labelled M. tuberculosis (Section 4.2.2). In the lungs, we would 
additionally include the analysis of neutrophils as they are phagocytic host 
cells relevant to the early time points being studied.  
 
We also propose to further our analysis of T cell responses in CLEC9A+ DC-
depleted mice infected with M. tuberculosis, in terms of the induction of IL-
17-producing γδ T cells and CD4+ Th17 cells, as well as CD8+ cytotoxic T 
lymphocytes (CTLs). IL-17 has been shown to enhance T cell-mediated IFNγ 
production and granuloma formation in response to pulmonary BCG infection 
(Umemura et al., 2007) and more recently, to be required in early protective 
immunity against “hypervirulent” M. tuberculosis clinical isolates (Gopal et 
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al., 2014). Unlike CD4+ Th17 cells, γδ T cell activation appears to be 
independent of classical MHCII-restricted presentation of peptide antigens by 
DCs; nonetheless, IL-17 production by both T cell lineages appears to be 
dependent on IL-23 which is produced by M. tuberculosis-infected DCs (Lim, 
Hong, Jung, Cho, & Kim, 2013; Khader & Cooper, 2008; Lockhart et al., 
2006). The Th17 response in the lung may be characterised by quantifying IL-
17, IL-23 and IL-12p401 levels in the BALF, and by detecting intracellular 
IL17A+ CD4+ Th17 cells by flow cytometry (de Jong, Suddason, & Lord, 
2010). γδ T cells are generally defined as γδ TCR+ CD4− CD8− (Lockhart et 
al., 2006). Induction of CD8+ CTLs involves cross-priming, a function that is 
reportedly executed by CLEC9A+ CD103+ and CD8+ cDCs but not CD11b+ 
cDCs (reviewed in Section 4.1). CD8+ CTLs may be defined by intracellular 
staining for granzyme B (Behar 2013). 
 
One of the advantages of an inducible depletion model is that we may control 
when depletion is induced. It would be interesting to investigate if depletion of 
CLEC9A+ DCs from 14 days post-infection instead would affect the immune 
control of infection any differently.  
 
Finally, Ruedl and colleagues at NTU have recently successfully generated a 
DC inhibitory receptor 2 (DCIR2)-DTR transgenic line with the same BALB/c 
                                                
1 IL-23 is a heterodimeric cytokine comprising of IL-12p19 and IL-12p40. 
The IL-12p40 subunit is shared with functional IL-12 (IL-12p70), which also 
requires IL-12p30. We were unable to consistently detect IL-12p70 in the 
BALF of our mice, an aspect that remains to be optimised. Alternatively, 
many groups have detected IL-12p40 as a measure of bioactive IL-12p70 with 
success, but with increasing recognition of the roles of IL-23 and IL-17, any 
implications of IL-12p40 should be evaluated with discernment.  
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background as the CLEC9A-DTR mice (personal communication; 
unpublished). DCIR2 is a type II transmembrane C-type lectin expressed on 
myeloid CD11c+ CD11b+ DCs in the lymphoid tissues but not on bone 
marrow cells, macrophages and other leukocytes (Idoyaga et al., 2013; 
Dudziak et al., 2007). In a model of influenza infection, Ruedl and colleagues 
have shown that DT administration to DCIR2-DTR transgenic mice can 
achieve partial ablation (approximately 50%) of CD24− CD11b+ DCs2 in the 
lungs (personal communication). Hence, this model may potentially be 
optimised to complement our work here in understanding the relative roles of 
pulmonary DC subsets in M. tuberculosis infection, specifically in the 
initiation of T cell responses and ultimately the control of mycobacterial 
proliferation. Whether infDCs express DCIR2 has yet to be clarified and 
should also be confirmed. 
 
  
                                                
2 CD24+ CD11b+ macrophages in the lungs can be distinguished from CD24− 
CD11b+ DCs based on CD24 expression. 
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+ DC pDC infDC Macrophage Ly6C+ Monocyte 
CD11b – + – + + + 
Ly6C – – ++ + + ++ 
CD206 – – (resident) + (migratory) – + + – 
FcɛRI – – – + – – 
CD64 – – – + ++ +/– 
CD11c ++ ++ + + +/– +/– 
CD172a – + – + + + 
F4/80 – + – + + + 
 
Note. Adapted from “Inflammatory dendritic cells in mice and humans” by E. 
Segura and S. Amigorena, 2013, Trends in Immunology 34(9), pp. 440-445. 
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5.1.  Concluding remarks 
In this Thesis, we reported and discussed our experimental findings pertaining 
to two aspects of host immunity to M. tuberculosis infection: the role of 
ANXA1, a protein expressed endogenously by a variety of immune cells, and 
the role of the CLEC9A+ DC subset, which includes CD103+ migratory DCs 
in the lungs. 
 
First, using an ANXA1−/− mouse model of pulmonary M. tuberculosis 
infection, we described how ANXA1 may influence the immune response to a 
chronic infectious disease. We showed that the pleiotropic anti-inflammatory 
effects of ANXA1 indeed play an important role in restraining the 
immunopathology induced by M. tuberculosis infection, specifically in terms 
of bacillary load and severity of granulomatous inflammation in the lungs. Our 
data suggest that in the context of M. tuberculosis infection, ANXA1 has little 
effect on the infection profile of macrophages, despite extensive 
documentation of the role of ANXA1 in modulating the activities of innate 
immune cells in models of acute inflammation. Instead, ANXA1 appears to be 
more critically involved in regulating the adaptive immune response via its 
impact on DC functions, specifically cytokine production, maturation and 
ability to activate naïve T cells. Our published findings are supported by 
another recently published report in which the group demonstrated that during 
M. tuberculosis infection, ANXA1 is an important mediator in DC cross-
presentation by increasing efferocytosis in DCs and enhancing the potential of 
DC antigen-presenting mechanisms (Tzelepis et al., 2014). 
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Second, using GFP-expressing bacteria, we showed that DCs increase in 
importance as a mycobacterial reservoir relative to their primary hosts, AMs, 
as M. tuberculosis infection progresses. Using CLEC9A-DTR transgenic mice 
enabling the inducible depletion of CLEC9A+ DCs, we established that 
CD103+ DCs contribute to the control of bacterial burden and play an 
important role in the initiation of T cell responses during M. tuberculosis 
infection. In view of the current literature and based on our data, we propose a 
crucial role for the lung CD103+ DC subset in the rapid mobilisation of 
bacteria from the lung to the draining LN soon after pulmonary exposure to M. 
tuberculosis, which is a critical determinant of host resistance.  
 
Both aspects of this Thesis underscore the significance of DCs in the host 
immune response to M. tuberculosis. The heterogeneity of DCs has only 
recently been appreciated, and our work sheds light on the specific roles of 
DC subsets during M. tuberculosis infection, in particular, the pulmonary 
CLEC9A+ CD103+ DC subset. Our findings are relevant to a time when new 
host-targeted approaches in the development of drugs and vaccines against 
infectious pathogens are gaining ground, and scientists in the TB field are 
urgently seeking to replace an out-dated and suboptimal BCG vaccine and to 
circumvent the burgeoning problem of antibiotic-resistance. One new strategy 
to enhance the effectiveness of vaccines is the selective delivery of antigens to 
DCs in situ via monoclonal antibodies specific for certain DC surface 
molecules. In particular, CLEC9A+ DCs are presently the most promising 
target, because they bear the greatest potential to generate CD8+ T cell 
responses including CTL induction via their specialised cross-presenting 
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capability (Sancho et al., 2008) and are major producers of IL-12p70 
(Hochrein et al., 2001). Furthermore, the human equivalent of the murine 
CLEC9A+ DC subset has also been identified (Dutertre, Wang & Ginhoux, 
2014; Caminschi et al., 2008; Huysamen, Willment, Dennehy, & Brown, 
2008), making research in mouse models highly translatable to human disease.  
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